

SHRI BALAJI INSTITUTE OF MEDICAL SCIENCE RAIPUR (C.G)

ACADEMIC TIME TABLE –MBBS BATCH 2024 PHASE II TEACHING SESSION - 08 OCT 2025 - SEPTEMBER 2026

ACADEMIC TIME TABLE – MBBS BATCH 2024 PHASE II TEACHING SESSION – 08 OCT 2025- SEPTEMBER 2026

PATHOLOGY	PHARMACOLOGY	MICROBIOLOGY	COMMUNITY MEDICINE	FORENSIC MEDICINE TOXICOLOGY	
TOTAL - 260	TOTAL - 260	TOTAL - 228	TOTAL -59	TOTAL -45	
LECTURE -80	LECTURE - 80	LECTURE - 75	LECTURE -25	LECTURE -12	
SGL - 170	SGL - 170	SGL - 143	SDL -10	SGL -25	
SDL -10	SDL - 10	SDL - 10	FAP - 24	SDL -08	
CLINICAL SUBJECTS- 60	CLINICAL POSTING	AETCOM	PANDEMIC TOTAL -28	SPORTS AND EXTRA CURRICULAR TOTAL - 32	Integration
LECTURES	540 HOURS	TOTAL -37	CM- 12		
GEN MEDICINE -20	MON- FRI	SGL -29	MI-10		
GEN SURGERY -20	3HRS/ DAY	SDL -08	PH-03		
OBGY -20	15HRS/WEEK	PATHOLOGY- 11	GM-03		
		PHARMACOLOGY- 10			
		MICROBIOLOGY - 11			
		FMT- 05			

SHRI BALAJI INSTITUTE OF MEDICAL SCIENCE RAIPUR (C.G)

ACADEMIC TIME TABLE –MBBS BATCH 2024 PHASE II TEACHING SESSION - 08 OCT 2025 - SEPTEMBER 2026

DATE	DAY	9.-10.00AM	10-01PM	L	2.00-3.00PM	3.00PM-4.00PM	4.00-5.00PM
08 OCT 2025	WED	01 OG 2.1 Basic anatomy	CLINICAL POSTING		MI 1.1 (L) Introduction & History of Microbiology, Bacterial Taxonomy	PPr (1.1) Introduction to Pathology (Batch B) PH Visit to Department Orientation to microbiology lab	
09 OCT 2025	THU	L – 01 PH 1.1 Describe the principles of pharmacology, pharmacotherapeutics and define various terms in pharmacology.	CLINICAL POSTING		L-01 IM 4.1, 4.2, Describe and discuss the febrile response and the influence of host immune status, risk factors and comorbidities on the febrile response. Describe and discuss the influence of special populations on the febrile response including: the elderly, immune suppression, malignancy and neutropenia. HIV and travel	MI1.2 (L) Morphology of Bacteria (part I)	PA L-1 (PA 1.1) Introduction to Pathology
10 OCT 2025	FRI	CM 8.1A Epidemiological characteristics and control measures including the use of essential laboratory tests at the primary care level for airborne infections & Exanthematous fevers Small pox, Chickepox (L-01)	CLINICAL POSTING		FM 1.1 Introduction to FMT-Theory	PAL-2 (PA 1.1) Introduction to Hematology	L-02 PH 1.2 Describe evidence-based medicine and rational use of drugs & discuss why these are relevant to therapeutics. PH 1.3 Describe nomenclature of drugs i.e., generic, branded drugs and scheduled drugs, explaining the utility of the nomenclature, cost effectiveness and use.
11 OCT 2025	SAT	MI1.2 (L) Morphology and physiology of Bacteria (part II)	PA SDL Museum Visit		L-03PH 1.6 - Pharmacokinetics Describe salient features of (Absorption)	SPORTS 01	

12 OCTOBER 2025 SUNDAY

SHRI BALAJI INSTITUTE OF MEDICAL SCIENCE RAIPUR (C.G)

ACADEMIC TIME TABLE –MBBS BATCH 2024 PHASE II TEACHING SESSION - 08 OCT 2025 - SEPTEMBER 2026

DATE	DAY	9.-10.00AM	10-01PM	L	2.00-3.00PM	3.00PM–4.00PM	4.00-5.00PM
13 OCT 2025	MON	L-01 Metabolic response to Injury SU1.1	CLINICAL POSTING		PA L-3 (PA10.1,10.2,10.3, 11.1,11.2) Haematology Basic, classification of Anaemia, Microcytic Hypochromic anaemia	PPr (1.1) Introduction to Pathology – Microscope, Books, Records (Batch A) PH – Practical -Visit to Museum & CAL lab MI 1.4 Handling and care of Microscope	
14 OCT 2025	TUE	L-04 PH 1.6 - Pharmacokinetics Describe salient features of (Distribution	CLINICAL POSTING		L-02 IM 4.3 Discuss and describe the common causes, pathophysiology and manifestations of fever in various regions in India including bacterial , parasitic and viral causes (e.g. Dengue, Chikunguniya. Typhus)	PPr (1.1) Introduction to Pathology – Microscope, Books, Records (Batch C) PH – Practical -Visit to Museum & CAL lab MI 1.4 Handling and care of Microscope	
15 OCT 2025	WED	L2 OG 2.1 Basic anatomy	CLINICAL POSTING		MI 1.5, 1.7 (L) Specimen collection and transport	PPr (1.1) Introduction to Pathology – Microscope, Books, Records (Batch B) PH – Practical -Visit to Museum & CAL lab MI 1.4 Handling and care of Microscope	
16 OCT 2025	THU	PA L-4 (PA12.1) Macrocytic anaemia & it's classification.	CLINICAL POSTING		L-05 PH 1.6 - Pharmacokinetics Describe salient features of (Metabolism)	MI 1.4, 11.1 (SGL) Culture Media , methods, and identification	FM 1.1 Introduction to FMT-Practical
17 OCT 2025	FRI	CM8.1A (L-02) Epidemiological characteristics and control measures including the use of essential laboratory tests at the primary care level for airborne infection & Exanthematous fevers 2. Measles, Rubella, Mumps	CLINICAL POSTING		FM 1.3 Legal Procedure	SPORTS 02	

18 TO 25 OCTOBER DEEPAWALI HOLIDAY

SHRI BALAJI INSTITUTE OF MEDICAL SCIENCE RAIPUR (C.G)

ACADEMIC TIME TABLE –MBBS BATCH 2024 PHASE II TEACHING SESSION - 08 OCT 2025 - SEPTEMBER 2026

DATE	DAY	9.-10.00AM	10-01PM	L	2.00-3.00PM	3.00PM–4.00PM	4.00-5.00PM
26 OCTOBER 2026 SUNDAY							
27 OCT 2025	MON	L-02 Metabolic response to Injury SU1.2	CLINICAL POSTING		PA L-5 (PA13.1,13.2) Haemolytic anaemia, Sickle cell anaemia.	PPr (6.1) Blood Banking - Types of Blood Samples, Anticoagulants and Blood Collection, Blood Groups, Compatibility Testing and Transfusion (Batch A) Practical - PH 1.4 (Batch- c) Identify the common drug formulations and drug delivery systems, demonstrate their use and describe their advantages and disadvantages. MI 1.4, 1.10 Staining methods (Gram staining: Principle and application)	
28 OCT 2025	TUE	L-06 PH 1.6 - Pharmacokinetics Describe salient features of (Excretion)	CLINICAL POSTING		L-03IM 4. 4,4.5 Describe and discuss the pathophysiology and manifestations of inflammatory causes of feve. Describe and discuss the pathophysiology and manifestations of malignant causes of fever including hematological and lymph node malignancies’.	PPr (6.1) Blood Banking - Types of Blood Samples, Anticoagulants and Blood Collection, Blood Groups, Compatibility Testing and Transfusion (Batch C) Practical - PH 1.4 (Batch- b) Identify the common drug formulations and drug delivery systems, demonstrate their use and describe their advantages and disadvantages. MI 1.4, 1.10 Staining methods (Gram staining: Principle and application)	
29 OCT 2005	WED	L -3 OG 3.1 Physiology of conception	CLINICAL POSTING		MI 1.3 (L) Bacterial Genetics	PPr (6.1) Blood Banking - Types of Blood Samples, Anticoagulants and Blood Collection, Blood Groups, Compatibility Testing and Transfusion (Batch B) Practical - PH 1.4 (Batch- a) Identify the common drug formulations and drug delivery systems, demonstrate their use and describe their advantages and disadvantages. MI 1.4, 1.10 Staining methods (Gram staining: Principle and application)	
30 OCT 2025	THU	PA L-6 (PA13.2,13.3) Thalassemia Hereditary spherocytosis and G6PD deficiency	CLINICAL POSTING		L - 07 PH 1.7 Describe various principles of mechanism of action of drugs	FM SGL 3 FM 1.3 Legal Procedure	AETCOM 01 PA 01 Aetcom-1 Module 2.1: The Foundation of Communication 2 – Introductory small group session
31 OCT 2025	FRI	Lec-01 FM 1.3 Legal Procedure	CLINICAL POSTING		SGD 6.2 Rhinosporidiosis/ Hydatid cyst	MI SGL 11.1, 11.2, 10.5 Antimicrobial agents and Antimicrobial Resistance	L – 08 PH 1.10 Describe changes in pharmacology of drugs in geriatric, pediatric and special situations such as Pregnancy, lactation, hepatic and renal disorders and adjust the drug treatment accordingly.



ACADEMIC TIME TABLE –MBBS BATCH 2024 PHASE II TEACHING SESSION - 08 OCT 2025 - SEPTEMBER 2026

01 NOV 2025	SAT	MI 1.1, 1.2 (L) Pathogenesis of Bacterial Infection	SURGERY/ AETCOM		SDL-01 CM 8.3 Outbreak investigation steps(case scenario)	PH – 08 (SGL) PH 1.11, 1.12 Pharmacovigilance	Sports 05
02 NOVEMBER 2025 SUNDAY							
DATE	DAY	9.-10.00AM	10-01PM	L	2.00-3.00PM	3.00PM–4.00PM	4.00-5.00PM
03 NOV 2025	MON	L-03Shock SU2.1.1	CLINICAL POSTING		PA L-7 (PA14.1) Leukaemia – Classification of Leukaemia, Acute Leukaemia	PPr (15.1) Physical and Chemical Examination of Urine (Batch A)	
						PH 1.5 Describe various routes of drug administrationadvantages anddisadvantages and demonstrate administration of, e.g., SC, IV, IM, SL,rectal, spinal, sublingual, intranasal sprays and inhalers	
						MI 1.4, 1.10Staining methods (Gram staining: Demonstration	
04 NOV 2025	TUE	PH 1.13 Drug Interaction	CLINICAL POSTING		L-04 IM 4.8 Discuss and describe the pathophysiology, aetiology and clinical manifestations of fever of unknown origin (FUO) including in a normal host neutropenic host nosocomial host and host with HIV disease	PPr (15.1) Physical and Chemical Examination of Urine (Batch C)	
						PH 1.5 Describe various routes of drug administrationadvantages anddisadvantages and demonstrate administration of, e.g., SC, IV, IM, SL,rectal, spinal, sublingual, intranasal sprays and inhalers	
						MI 1.4, 1.10 Staining methods (Gram staining: Demonstration	
05 NOVEMBER 2025 GURU NANAK JAYANTI							
06 NOV 2025	THU	PA L-8 (PA14.1) Chronic leukaemia.	CLINICAL POSTING		L-PH 2.1 Introduction to ANS	FM SGL 4	AETCOM 02 MI-01
						FM 1.3 Legal Procedure	MI 2.2 AETCOM in Microbiology
07 NOV 2025	FRI	M0d 2.2.1 Emergence and Re- emergence of Microbes. Exploratory and Interactive theory session	CLINICAL POSTING		SDL-01 PH 2.2 Cholinergic Drugs	PA Tutorial 1.1 Approach to investigation of Anemia	PANDEMIC-01 MI
							PM 2.1 Infection Control: Air borne precautions
08 NOV 2025	SAT	MI 1.11 Epidemiology of infectious disease (L	PH 2.2 OPC Poisoning + Myasthenia Gravis		PA SDL-01 Case Discussion (Hematology)	MI 1.4, 11.1 Culture Media , methods, and identification (SGL)	Sports 06
09 NOVEMBER 2025 SUNDAY							

SHRI BALAJI INSTITUTE OF MEDICAL SCIENCE RAIPUR (C.G)

ACADEMIC TIME TABLE –MBBS BATCH 2024 PHASE II TEACHING SESSION - 08 OCT 2025 - SEPTEMBER 2026

DATE	DAY	9.-10.00AM	10-01PM	L	2.00-3.00PM	3.00PM-4.00PM	4.00-5.00PM
10 NOV 2025	MON	L-04 Shock SU2.1.2	CLINICAL POSTING		L(PA15.1)Hodgkin's Lymphoma & its classification.	PPr (15.2) Microscopic Examination of Urine (Batch A) PH 1.5 Describe various routes of drug administration advantages and disadvantages and demonstrate administration of, e.g., SC, IV, IM, SL, rectal, spinal, sublingual, intranasal sprays and inhalers MI 1.4, 1.10 Staining methods (Gram staining): DOAP	
11 NOV 2025	TUE	L-07 PH 2.2 Anti Cholinergic	CLINICAL POSTING		L-05 IM 4.16, 4.18 Enumerate the indications and describe the findings in tests of inflammation and specific rheumatologic tests, serologic testing for pathogens including HIV, bone marrow aspiration and biopsy. Enumerate the indications for use of imaging in the diagnosis of febrile syndromes.	PPr (15.2) Microscopic Examination of Urine (Batch C) PH 1.5 Describe various routes of drug administration advantages and disadvantages and demonstrate administration of, e.g., SC, IV, IM, SL, rectal, spinal, sublingual, intranasal sprays and inhalers MI 1.4, 1.10 Staining methods (Gram staining): DOAP	
12 NOV 2025	WED	L- 4 OG 3.1 Physiology of conception	CLINICAL POSTING		MI 1.1, 1.2 Overview of bacterial infection (SGL)	PPr (15.2) Microscopic Examination of Urine (Batch B) PH 1.5 Describe various routes of drug administration advantages and disadvantages and demonstrate administration of, e.g., SC, IV, IM, SL, rectal, spinal, sublingual, intranasal sprays and inhalers MI 1.4, 1.10 Staining methods (Gram staining): DOAP	
13 NOV 2025	THU	PA L-10 (PA15.1) Non-Hodgkin's Lymphoma & its classification.	CLINICAL POSTING		PH L-08 PH 2.1 Adrenergic Drugs	FM SGL 5 FM 3.1.1 Identification (Introduction, Types & data of Identification) Corpus Delict	AETCOM 03 PH 01 Module 2.1 (1)(Demonstrate ability to communicate to patients in a patient, respectful, non-threatening, non-judgmental and empathetic manner.)
14 NOV 2025	FRI	FM-02 FM 3.2.2 Identification (Dactylography Poroscopy Lip Print, Foot Print)	CLINICAL POSTING		PA Seminar-1 Disorders caused by air pollution, tobacco and alcohol	MI 1.1, 1.2, 1.4 to 1.6, 1.10 Overview of parasitic infection (SGL)	CM 8.1A Epidemiological characteristics & control measures including the use of essential laboratory tests at the primary care level. 3. Diphtheria, whooping cough, Meningococcal meningitis
15 NOV 2025	SAT	MI 1.1, 1.2, 1.4 to 1.6 Overview of General Virology I (L)	PA SGD2.1 Aspergillosis / Cysticercosis		PH 2.1 Alpha Blockers	PA Tutorial 1.2 Hemolytic anemia	Sports 07

16 NOVEMBER 2025 SUNDAY

SHRI BALAJI INSTITUTE OF MEDICAL SCIENCE RAIPUR (C.G)

ACADEMIC TIME TABLE –MBBS BATCH 2024 PHASE II TEACHING SESSION - 08 OCT 2025 - SEPTEMBER 2026

DATE	DAY	9.-10.00AM	10-01PM	L	2.00-3.00PM	3.00PM-4.00PM	4.00-5.00PM
17 NOV 2025	MON	L-05 Shock SU2.2.1	CLINICAL POSTING		PA L-11(PA15.2) Multiple Myeloma.	PPr Basic Cytopathologic Techniques and their Applications (Interpretation of Pap Smear and Fluid Cytology, Interpretation of FNA Procedure). (Batch A) PH 1.12 Define Pharmacovigilance its principles and demonstrate ADRreporting MI 1.4, 11.1 Culture Media & instruments	
18 NOV 2025	TUE	L-09 PH 2.1 Beta Blockers	CLINICAL POSTING		L-06 IM 4.7 Discuss and describe the pathophysiology and manifestations of the Sepsis Syndrome.	PPr Basic Cytopathologic Techniques and their Applications (Interpretation of Pap Smear and Fluid Cytology, Interpretation of FNA Procedure). (Batch C) PH 1.12 Define Pharmacovigilance its principles and demonstrate ADRreporting MI 1.4, 11.1 Culture Media & instruments	
19 NOV 2025	WED	L 05 OG 4.1 Development of the placenta	CLINICAL POSTING		MI 1.1, 1.2, 1.4 to 1.6 Overview of General Virology II (L)	PPr Basic Cytopathologic Techniques and their Applications (Interpretation of Pap Smear and Fluid Cytology, Interpretation of FNA Procedure). (Batch B) PH 1.12 Define Pharmacovigilance its principles and demonstrate ADRreporting MI 1.4, 11.1 Culture Media & instruments	
20 NOV 2025	THU	PA L-12 (PA16.1) Haemorrhagic disorders: Classify	CLINICAL POSTING		FM 3.1.2 Identification (Odontology)	SGL 5PH 2.4 Skeletal Muscle Relaxants (SMR)	AETCOM 04 PA 02 Aetcom-2 Module 2.1: The Foundation of Communication 2 – Focused small group session
21 NOV 2025	FRI	Epidemiological characteristics & control measures including the use of essential laboratory tests at the primary care level.4. COVID-19	CLINICAL POSTING		PHPH 2.5 Local Anesthesia (LA)	PA SDL – 2 Case discussion	PANDEMIC-03 MI PM 2.1 Infection Control: Contact Precautions
22 NOV 2025	SAT	MI 1.1 Normal Human Microbiota (L)	PH 2.6 Anti – histaminics		PA Seminar-2 Genetic Disorders I – Down Syndrome / Edward Syndrome / Klinefelter syndrome / Turner syndrome	MI 1.1, 1.2, 1.4 to 1.6 Overview of Fungal infection (SGL)	Sports 08

23 NOVEMBER 2025 SUNDAY

SHRI BALAJI INSTITUTE OF MEDICAL SCIENCE RAIPUR (C.G)

ACADEMIC TIME TABLE –MBBS BATCH 2024 PHASE II TEACHING SESSION - 08 OCT 2025 - SEPTEMBER 2026

DATE	DAY	9.-10.00AM	10-01PM	L	2.00-3.00PM	3.00PM–4.00PM	4.00-5.00PM
24 NOV 2025	MON	L-06 Blood and its components SU3.1.1	CLINICAL POSTING		PA L-13 (PA 16.2) Screening tests for haemorrhagic disorders	PPr (6.2) ESR, PCV (Hematocrit) and Hemoglobin Estimation (Batch A) PH 1.12 Define Pharmacovigilance its principles and demonstrate ADR reporting MI 1.4, 1.10 Staining methods (ZN staining): principle and application	
25 NOV 2025	TUE	PH 2.7 NSAID's	CLINICAL POSTING		L-07 IM 4.6 Discuss and describe the pathophysiology and manifestations of malaria IM 4.22 Describe and discuss the pharmacology. Indications, adverse reactions, interactions of antimalaria drugs and basis of resistance	PPr (6.2) ESR, PCV (Hematocrit) and Hemoglobin Estimation (Batch C) PH 1.12 Define Pharmacovigilance its principles and demonstrate ADR reporting MI 1.4, 1.10 Staining methods (ZN staining): principle and application	
26 NOV 2025	WED	L-06 OG 4.1 Development of the fetus and the membranes	CLINICAL POSTING		MI 1.12, 1.13 Sterilization & disinfection-I (L)	PPr (6.2) ESR, PCV (Hematocrit) and Hemoglobin Estimation (Batch B) PH 1.12 Define Pharmacovigilance its principles and demonstrate ADR reporting MI 1.4, 1.10 Staining methods (ZN staining): principle and application	
27 NOV 2025	THU	PA L-14 (PA2.1,2.2) Cell injury Reversible & Irreversible	CLINICAL POSTING		L-12 PH 3.1 General Anesthesia + Pre-anesthetic medication	FM 3.2.3 Identification (Religions Tattoo Marks, Stature, Anthropometry)	AETCOM 05 MI-02 2.2 A Describe and discuss the role of non-maleficence as a guiding principle in patient care 2.2 A
28 NOV 2025	FRI	FM L-03 Identification (Scars, Birth Mark, Congenital Deformity, Living Data)	CLINICAL POSTING		PA SGD 10.1 Etiopathogenesis of Malaria (P.F.) / Leprosy / Tuberculosis	MI 1.12, 1.13 Sterilization & disinfection-II (L)	AETCOM 06 FM 2.6 Bioethics: Case Studies on Autonomy & Decision Making
29 NOV	SAT	MI 2.1 IMMUNITY –Innate and acquired (L)	MI 2.2 Structure of Antigen, Antibody (SGL)		SDL-02 CM8.1 COVID 19 lessons (Reflective writing)	PH 3.2 Sedative Hypnotics	Sports 09

30 NOVEMBER 2025 SUNDAY



ACADEMIC TIME TABLE –MBBS BATCH 2024 PHASE II TEACHING SESSION - 08 OCT 2025 - SEPTEMBER 2026

DATE	DAY	9.-10.00AM	10-01PM	L	2.00-3.00PM	3.00PM–4.00PM	4.00-5.00PM
01 DEC 2025	MON	L-07Wound healing and wound care chapter 3 & 4 LOVE & BAILEY SU5.1.1	CLINICAL POSTING		PA L-15 (PA2.4) Apoptosis.	PPr (6.3) Preparation and Staining of Peripheral Blood Smear, Differential Leucocyte Count (Batch A)	
						PH 1.13 Identify and describe the management of drug interactions	
						MI 1.4, 1.10 Staining methods (ZN staining): Demonstration	
02 DEC 2025	TUE	L-13PH 3.3 Epilepsy	CLINICAL POSTING		L-08 IM 25.1, 25.2, 25.8 Describe and discuss the response and the influence of host. immune status, risk factors and comorbidities on zoonotic diseases (e.g. Leptospirosis.Rabies) and non-febrile infectious disease (e.g. Tetanus).Discuss and describe the commoncauses, pathophysiology and manifestations of these diseases Enumerate the indications for use of newer techniques in the diagnosis of these infections	PPr (6.3) Preparation and Staining of Peripheral Blood Smear, Differential Leucocyte Count (Batch C)	
						PH 1.13 Identify and describe the management of drug interactions	
						MI 1.4, 1.10 Staining methods (ZN staining): Demonstration	
03 DEC 2025	WED	L-07 OG 6.1 Diagnosis of Pregnancy	CLINICAL POSTING		MI	PPr (6.3) Preparation and Staining of Peripheral Blood Smear, Differential Leucocyte Count (Batch B)	
						PH 1.13 Identify and describe the management of drug interactions	
						MI 1.4, 1.10 Staining methods (ZN staining): Demonstration	
04 DEC 2025	THU	PA L-16 (PA2.3,2.4) Intracellularaccumulations& alterations Calcificationand Gangrene Cellularageing. (+2 Hours)	CLINICAL POSTING		L-14 PH 3.4 Opioids – I	FM SGL 8	AETCOM 07 PH -02
						Identification (DNA Profiling)	Module 2.1 (2)(Demonstrate ability to communicate to patients in a patient, respectful, non-threatening, non-judgmental and empathetic manner.)
05 DEC 2025	FRI	CM 8.1AEpidemiological characteristics and control measures including the use of essential laboratory tests at the primary care level for Airborne infections & Exanthematous fevers (Lecture-05) 5) Influenza, ARI & SARS	CLINICAL POSTING		PA Tutorial 2.1 TFT	MI 2.5 Antigen-antibody reaction–I I (L)	PANDEMIC-04 CM PM 2.2 MOD 2.2.2 Emergence and Re-emergence of Microbes. Small group assignment / Self study Covid-19
06 DEC	SAT	MI 2.2 Complement system (L)	SURGERY/ AETCOM		SGL PH 3.4 Opioids – II	PA SDL Poster making	Sports 10
07 DECEMBER 2025 SUNDAY							

SHRI BALAJI INSTITUTE OF MEDICAL SCIENCE RAIPUR (C.G)

ACADEMIC TIME TABLE –MBBS BATCH 2024 PHASE II TEACHING SESSION - 08 OCT 2025 - SEPTEMBER 2026

DATE	DAY	9.-10.00AM	10-01PM	L	2.00-3.00PM	3.00PM-4.00PM	4.00-5.00PM
08 DEC 2025	MON	L-08 Wound healing and wound care chapter 3 & 4 LOVE & BAILEY SU5.3.1	CLINICAL POSTING		PA L-17 (PA2.5) Apoptosis & its relevance. Difference Between Apoptosis and Necrosis	PPr Bone Marrow Aspiration & CSF collection techniques and their applications. (Batch A)	
						PH 10.1 Compare and contrast different sources of drug information and update on latest information on drugs.	
						MI 1.4, 1.10 Staining methods (ZN staining): DOAP	
09 DEC 2025	TUE	PH 3.5 Antidepressants & Antipsychotics - I	CLINICAL POSTING		L-09 IM 23.1, 23.2, 23.4 Discuss and describe the methods of nutritional assessment in an adult and calculation of caloric requirements during illnesses. Discuss and describe the causes and consequences of protein caloric malnutrition in the hospital. Enumerate the indications for enteral and parenteral nutrition in critically ill patients	PPr Bone Marrow Aspiration & CSF collection techniques and their applications. (Batch C)	
						PH 10.1 Compare and contrast different sources of drug information and update on latest information on drugs.	
						MI 1.4, 1.10 Staining methods (ZN staining): DOAP	
10 DEC 2025	WED	L-08 OG 7.1 Maternal Changes in Pregnancy	CLINICAL POSTING		MI 2.2 Structure & Function of immunesystem I (L)	PPr Bone Marrow Aspiration & CSF collection techniques and their applications. (Batch B)	
						PH 10.1 Compare and contrast different sources of drug information and update on latest information on drugs.	
						MI 1.4, 1.10 Staining methods (ZN staining): DOAP	
11 DEC 2025	THU	PA L-18 (PA2.6) Calcification and 1 Gangrene, Cellular ageing and mechanism	CLINICAL POSTING		L-16 PH 3.5 Antidepressants & Antipsychotics - II	FM SGL 9 Bone Examination (Skull, Mandible)	AETCOM 08 PA 03
							Aetcom-3 Module 2.1: The Foundation of Communication 2 – Skills lab session
12 DEC 2025	FRI	FM L-04 Bone Examination (Upper Extremity, Sternum, Clavicle, Scapula)	CLINICAL POSTING		MI 2.2 Structure & Function of immunesystem II (SDL)	PA Seminar-3 Genetic Disorders II – Neurofibromas Schwannomas / Myasthenia Gravis / DMD / BMD	PANDEMIC 05-CM
							PM 2.3 MOD 2.2.2 Emergence and Re-emergence of Microbes. Small group assignment / Self study Zika & Nipah Virus Disease
13 DEC 2025	SAT	MI 2.3, 2.4 CMI (L)	PA SGD 36.1 Neuroblastoma / Retinoblastoma / Wilms Tumor		PH 3.6 Anxiety & Antimanic Drugs - I	MI 2.3, 2.4 AMI (L)	Sports 11

14 DECEMBER 2025 SUNDAY



ACADEMIC TIME TABLE –MBBS BATCH 2024 PHASE II TEACHING SESSION - 08 OCT 2025 - SEPTEMBER 2026

DATE	DAY	9.-10.00AM	10-01PM	L	2.00-3.00PM	3.00PM-4.00PM	4.00-5.00PM
15 DEC 2025	MON	L-09Wound healing and wound care chapter 3 & 4 LOVE & BAILEY SU 5.3.2	CLINICAL POSTING		PA L-19 (PA4.1) Acuteinflammation.	PPr Approach to Investigation in Anemia (Batch A)	
						PH 10.1 Compare and contrast different sources of drug information and update on latest information on drugs.	
						MI 1.4, 1.10 Manual checking and viva	
16 DEC 2025	TUE	L-17PH 3.6 Anxiety & Antimanic Drugs - II	CLINICAL POSTING		L-10 IM 23. Discuss and describe the aetiology. causes. clinical manifestations, complications, diagnosis and management of common vitamin deficiencies	PPr Approach to Investigation in Anemia (Batch C)	
						PH 10.1 Compare and contrast different sources of drug information and update on latest information on drugs.	
						MI 1.4, 1.10 Manual checking and viva	
17 DEC 2025	WED	L-09 OG 8.1 Antenatal assessment of fetal well being	CLINICAL POSTING		MI 2.7 Hypersensitivity-I (L)	PPr Approach to Investigation in Anemia (Batch C)	
						PH 10.1 Compare and contrast different sources of drug information and update on latest information on drugs.	
						MI 1.4, 1.10 Manual checking and viva	
18 DECEMBER 2025 GURU GHASIDAS JAYANTI							
19 DEC 2025	FRI	CM 8.1A Epidemiological characteristics and control measures including the use of essential laboratory tests at the primary care level for Airborne infections & Exanthematous fevers (Lecture-06) 6) Tuberculosis	CLINICAL POSTING		PPTutorial 2.3 Diabetes Mellitus	FM SGL 10 Bone Examination (Lower Extremity, Pelvis, Sacrum)	AETCOM 09 MI -03
							2.2 A Describe and discuss the role of non-malignance as a guiding principle in patient care
20 DEC 2025	SAT	MI 2.7 Hypersensitivity-II (SGL)	CLASSESSPH 3.7 Drugs for Parkinsonism		CM17.5 My first visit to a Primary Health Centre – learning about rural health care delivery system (Reflective writing)- SDL-03	SGLPH 3.8 Alcohol	Sports 12
21 DECEMBER 2025 SUNDAY							



25 DECEMBER 2025 CHRISTMAS

28 DECEMBER 2025 SUNDAY

SHRI BALAJI INSTITUTE OF MEDICAL SCIENCE RAIPUR (C.G)

ACADEMIC TIME TABLE –MBBS BATCH 2024 PHASE II TEACHING SESSION - 08 OCT 2025 - SEPTEMBER 2026

DATE	DAY	9.-10.00AM	10-01PM	L	2.00-3.00PM	3.00PM-4.00PM	4.00-5.00PM
29 DEC 2025	MON	L-11Surgical Infection Tropical infection and infestation SU6.2.1	CLINICAL POSTING		PA L-21 (PA4.2) Chemical mediators.	PPr (14.1,2.1) Screening Tests for Hemostasis, PS Interpretation of Platelet Disorders (Batch A) PH 10.3 To prepare and explain a list of P-drugs for a given case/condition MI 2.2, 2.7 CBL on hypoersensitivity reaction	
30 DEC 2025	TUE	L-19PH 4.2 Anti-coagulants	CLINICAL POSTING		L-12 IM 16.3, 16.6, 16.11Describe and discuss the chronic effects of diarrhoea including malabsorption Distinguish between diarrhoea and dysentery based on clinical features Enumerate the indications for stool cultures and blood cultures in patients with acute diarrhoea	PPr (14.1,2.1) Screening Tests for Hemostasis, PS Interpretation of Platelet Disorders (Batch C) PH 10.3 To prepare and explain a list of P-drugs for a given case/condition MI 2.2, 2.7 CBL on hypoersensitivity reaction	
31 DEC 2025	WED	L -11 OG 5.1 5.2 Pre-natal counselling screening & diagnosis	CLINICAL POSTING		MI2.7 Autoimmunity (SGL)	PPr (14.1,2.1) Screening Tests for Hemostasis, PS Interpretation of Platelet Disorders (Batch B) PH 10.3 To prepare and explain a list of P-drugs for a given case/condition MI 2.2, 2.7 CBL on hypoersensitivity reaction	
01 JAN 2026	THU	PA L-22 (PA4.4) Cell regeneration& repair.	CLINICAL POSTING		L-20 PH 4.3 Fibrinolytics	FM SGL 11 FM-14.4 Age Estimation	AETCOM 10 PH-03 Module 2.1 (3) (Demonstrate ability to communicate to patients in a patient, respectful, non-threatening, non-judgmental and empathetic manner.)
02 JAN 2026	FRI	CM 8.1AEpidemiological characteristics and control measures including the use of essential laboratory tests at the primary care level for Airborne infections & Exanthematous fevers (Lecture-07). 7) Tuberculosis	CLINICAL POSTING		MI 10.1, 10.2, 10.3, 10.5 Healthcare associated infections	PHPH 4.4 Antiplatelet Drugs	AETCOM 11 FM 02 2.6 Bioethics : Case Studies on Autonomy & Decision Making
03 JAN 2026	SAT	MI 10.1, 10.2 Major healthcare associated infection types (L)	SURGERY/ AETCOM		PH 4.5 Diuretics	MI 10.2 BMW (L)	Sports 14

04 JANUARY 2026 SUNDAY

SHRI BALAJI INSTITUTE OF MEDICAL SCIENCE RAIPUR (C.G)

ACADEMIC TIME TABLE –MBBS BATCH 2024 PHASE II TEACHING SESSION - 08 OCT 2025 - SEPTEMBER 2026

DATE	DAY	9.00-10.00AM	10-01PM	L	2.00-3.00PM	3.00PM-4.00PM	4.00-5.00PM
05 JAN 2026	MON	L-12Surgical Infection Tropical infection and infestation SU 6.2.	CLINICAL POSTING		PA L-23 (PA4.4) Healing by primary & secondary intention with local & systemic factors affecting wound healing.Repair in specialized tissue:	PPr Routine Histopathology Techniques and Staining. (Batch A) PH 10.3 To prepare and explain a list of P-drugs for a given case/condition MI 1.4, 1.1Staining methods Gram's staining): revision	
06 JAN 2026	TUE	L-21PH 4.6 Drugs modulating RAS	CLINICAL POSTING		L-13 IM 16.12,16.13,16.14 Enumerate and discuss the indications for further investigations including antibodies, colonoscopy, diagnostic imaging and biopsy in the diagnosis of chronic diarrhoea Describe and enumerate the indications. pharmacology and side effects of pharmacotherapy for parasitic causes of diarrhoea Describe, enumerate the indications, pharmacology and side effects of drugs for bacterial and viral diarrhoea	PPr Routine Histopathology Techniques and Staining. (Batch C) PH 10.3 To prepare and explain a list of P-drugs for a given case/condition MI 1.4, 1.10 Staining methods Gram's staining): revision	
07 JAN 2026	WED	L-12 OG 8.6 8.7 Diet nutrition in Pregnancy vaccination in Pregnancy	CLINICAL POSTING		MI MI 10.2 NSI (L)	PPr Routine Histopathology Techniques and Staining. (Batch C) PH 10.3 To prepare and explain a list of P-drugs for a given case/condition MI 1.4, 1.10 Staining methods Gram's staining): revision	
08 JAN 2026	THU	PA L-24 (PA 6.2) Haemostasis	CLINICAL POSTING		L-22PH 4.8 Drugs for Angina & MI	FM SGL 12 FM-14.4 Age Estimation	AETCOM 12 PA 04 Aetcom-4 Module 2.1: The Foundation of Communication 2- Discussion and closure
09 JAN 2026	FRI	FM L-06 FM-3.3 Mechanical Injuries (Introduction & Classification)	CLINICAL POSTING		PA SGD 11.3 Lysosomal storage disease	PH 4.9 Drugs for Heart Failure	PANDEMIC-7 MI PM 2.1Infection Control: Infection Control Committee
10 JAN 2026	SAT	MI MI 11.3 AMSP (L)	PA EXTRA/ REVISION CLASSESS		PH 4.10 Antiarrhythmic Drugs	MI MI 3.1 to 3.4, 3.9, 3.10 Infective Endocarditis (L)	Sports 15

11 JANUARY 2026 SUNDAY

SHRI BALAJI INSTITUTE OF MEDICAL SCIENCE RAIPUR (C.G)

ACADEMIC TIME TABLE –MBBS BATCH 2024 PHASE II TEACHING SESSION - 08 OCT 2025 - SEPTEMBER 2026

DATE	DAY	9.00-10.00AM	10-01PM	L	2.00-3.00PM	3.00PM-4.00PM	4.00-5.00PM
12 JAN 2026	MON	L-13 Investigation of surgical patient chapter 8, 11,12 SU9.1.1	CLINICAL POSTING		PA L-25 (PA6.1) Edema Hyperemia, congestion	PPr Cell Injury: Necrosis, Gangrene and Pathologic Calcification, Intracellular Accumulations. (Batch A)	
						PH 10.4 Describe parts of a correct, rational, and legible prescription and write rational prescriptions for the provided condition. (examples of conditions to be used are given with other relevant competencies).	
						MI 1.4, 1.10 Staining methods ZN staining): revision	
13 JAN 2026	TUE	L-23 PH 4.11 Drugs for Dyslipidemias	CLINICAL POSTING		L-14 IM16.15,16.16,16.17 Distinguish based on the clinical presentation Crohn 's disease from Ulcerative Colitis Describe and the indications, pharmacology and side effects of pharmacotherapy including immunotherapy Describe and enumerate the indications for surgery in inflammatory bowel disease	PPr Cell Injury: Necrosis, Gangrene and Pathologic Calcification, Intracellular Accumulations. (Batch C)	
						PH 10.4 Describe parts of a correct, rational, and legible prescription and write rational prescriptions for the provided condition. (examples of conditions to be used are given with other relevant competencies).	
						MI 1.4, 1.10 Staining methods ZN staining): revision	
14 JAN 2026	WED	L-13 OG 20.1 20.2 Medical termination of pregnancy	CLINICAL POSTING		MI 3.1 to 3.4, 3.9, 3.10 Acute Rheumatic Fever (L)	PPr Cell Injury: Necrosis, Gangrene and Pathologic Calcification, Intracellular Accumulations. (Batch B)	
						PH 10.4 Describe parts of a correct, rational, and legible prescription and write rational prescriptions for the provided condition. (examples of conditions to be used are given with other relevant competencies).	
						MI 1.4, 1.10 Staining methods ZN staining): revision	
15 JAN 2026	THU	PA L-26 (PA6.3,6.4) Thrombosis.	CLINICAL POSTING		L-24 PH 5.1 Drugs for Bronchial Asthma	FM SGL 13	AETCOM 13 MI-04
						FM-3.3 Mechanical Injuries (Abrasion)	2.2 Describe and discuss the role of autonomy and shared responsibility as a guiding principle in patient care
16 JAN 2026	FRI	CM 8.1B Epidemiological characteristics and control measures including the use of essential laboratory tests at the primary care level for Faeco-oral diseases. (Lecture-08) Poliomyelitis	CLINICAL POSTING		MI 3.3. 3.5, 3.9 BSI (SGL)	PA Tutorial 2.4 Hypersensitivity reaction	FM SDL-002 FM-3.3 Mechanical Injuries (Bruise)
17 JAN 2026	SAT	MI 3.6, 3.7, 3.8 Enteric Fever (L)	PH 5.2 Drugs for		PA SDL Reflection Writing	PH 6.1 Drugs for Peptic Ulcer	Sports 16

18 JANUARY 2026 SUNDAY



SHRI BALAJI INSTITUTE OF MEDICAL SCIENCE RAIPUR (C.G)

ACADEMIC TIME TABLE –MBBS BATCH 2024 PHASE II TEACHING SESSION - 08 OCT 2025 - SEPTEMBER 2026

DATE	DAY	9.00-10.00AM	10-01PM	L	2.00-3.00PM	3.00PM-4.00PM	4.00-5.00PM
19 JAN 2026	MON	L 14 Investigation of surgical patient chapter 8, 11,12 SU9.2.1	CLINICAL POSTING		PA L-27 (PA6.5,6.6) Embolism, Infarction Shock.	PPr (3.1) Acute and Chronic Inflammation, Granulomatous Inflammation (Batch A) PH 10.4 Describe parts of a correct, rational, and legible prescription and write rational prescriptions for the provided condition. (examples of conditions to be used are given with other relevant competencies).	MI 10.1, 10.2 CBL on BMW, NSI and HIC
20 JAN 2026	TUE	PHPH 6.2 Drugs for Emesis	CLINICAL POSTING		L- 15 IM 15.1,15.6,15.3,15.2 Enumerate, describe and discuss the aetiology of upper and lower GI bleeding Distinguish between upper and lower gastrointestinal bleeding based on the clinical features Describe and discuss the physiologic effects of acute blood and volume loss Enumerate, describe and discuss the evaluation and steps involved in stabilizing a patient who presents with acute volume loss and GI bleed	PPr (3.1) Acute and Chronic Inflammation, Granulomatous Inflammation (Batch C) PH 10.4 Describe parts of a correct, rational, and legible prescription and write rational prescriptions for the provided condition. (examples of conditions to be used are given with other relevant competencies).	MI 10.1, 10.2 CBL on BMW, NSI and HIC
21 JAN 2026	WED	L-14 OG 13.1 Normal Labour	CLINICAL POSTING		MIMI 1.1, 1.6 (SGL) Ricketssial infection	PPr (3.1) Acute and Chronic Inflammation, Granulomatous Inflammation (Batch B) PH 10.4 Describe parts of a correct, rational, and legible prescription and write rational prescriptions for the provided condition. (examples of conditions to be used are given with other relevant competencies).	MI 10.1, 10.2 CBL on BMW, NSI and HIC

1st TERMINAL EXAMINATION (22 JANUARY TO 3 FEBRUARY 2026)

DATE	DAYS	SUBJECT	TIME
22/01/2026	THURSDAY	PATHOLOGY	10AM-1PM
23/01/2026	FRIDAY	PHARMACOLOGY	10AM -1PM
24/01/2026	SATURDAY	MICROBIOLOGY	10AM-1PM
25 JANUARY 2026 SUNDAY			
26 JANUARY 2026 REPUBLIC DAY			
27/01/2026	TUESDAY	COMMUNINTY MEDICINE	10AM-1PM
28/01/2026	WEDNESDAY	FORENSIC MEDICINE	10AM-1PM

SHRI BALAJI INSTITUTE OF MEDICAL SCIENCE RAIPUR (C.G.)

ACADEMIC TIME TABLE –MBBS BATCH 2024 PHASE II TEACHING SESSION - 08 OCT 2025 - SEPTEMBER 2026

1 st TERMINAL PRACTICAL EXAMINATION						
DATE	DAYS	PATHOLOGY	PHARMACOLOGY	MICROBIOLOGY	COMMUNITY MEDICINE	FORENSIC MEDICINE
29/01/2026	THURSDAY	BATCH - A (1-30)	BATCH- B (31-60)	BATCH -C (61-90)	BATCH - D (91-120)	BATCH -E (121-150 & 81 A)
30/01/2026	FRIDAY	BATCH -E (121-150 & 81 A)	BATCH - A (1-30)	BATCH- B (31-60)	BATCH -C (61-90)	BATCH - D (91-120)
31/01/2026	SATURDAY	BATCH - D (91-120)	BATCH -E (121-150 & 81 A)	BATCH - A (1-30)	BATCH- B (31-60)	BATCH -C (61-90)
02/02/2026	MONDAY	BATCH -C (61-90)	BATCH - D (91-120)	BATCH -E (121-150 & 81 A)	BATCH - A (1-30)	BATCH- B (31-60)
03/02/2026	TUESDAY	BATCH- B (31-60)	BATCH -C (61-90)	BATCH - D (91-120)	BATCH -E (121-150 & 81 A)	BATCH - A (1-30)

EPT. OF PATHOLOGY
HOD SIGN. 
Dept. of Pathology
Shri Balaji Institute of Medical Science
Mowa, Raipur (C.G.)

EPT. OF GEN. SURGERY
HOD SIGN. 
HOD
Shri Balaji Institute of Medical Science
Mowa, Raipur (C.G.)

IEU CO-ORDINATOR


MEU
Shri Balaji Institute of Medical Science
Mowa, Raipur (C.G.)

DEPT. OF PHARMACOLOGY
HOD SIGN. 
HOD
Shri Balaji Institute of Medical Science
Mowa, Raipur (C.G.)


DEPT. OF OBS & GYNAC
HOD SIGN. 
HOD
Shri Balaji Institute of Medical Science
Mowa, Raipur (C.G.)

ACADEMIC DEAN

SBIMS
Shri Balaji Institute of Medical Science
Mowa, Raipur (C.G.)

DEPT. OF MICROBIOLOGY
HOD SIGN. 
HOD
Shri Balaji Institute of Medical Science
Mowa, Raipur (C.G.)

DEPT. OF COMM. MED.
HOD SIGN. 
HOD
Shri Balaji Institute of Medical Science
Mowa, Raipur (C.G.)

DEAN

SBIMS
Shri Balaji Institute of Medical Science
Mowa, Raipur (C.G.)

DEPT. OF GEN. MEDICINE
HOD SIGN. 
HOD
Shri Balaji Institute of Medical Science
Mowa, Raipur (C.G.)

DEPT. OF FMT.
HOD SIGN. 
HOD
Shri Balaji Institute of Medical Science
Mowa, Raipur (C.G.)

CHAIRMAN

SBIMS
Shri Balaji Institute of Medical Science
Mowa, Raipur (C.G.)

SHRI BALAJI INSTITUTE OF MEDICAL SCIENCE RAIPUR (C.G)

ACADEMIC TIME TABLE –MBBS BATCH 2024 PHASE II TEACHING SESSION - 08 OCT 2025 - SEPTEMBER 2026

DATE	DAY	9.-10.00AM	10-01PM	L	2.00-3.00PM	3.00PM–4.00PM	4.00-5.00PM
04 FEB 2026	WED	OG-15 OG 13.1 The fetus – physiology circulation	CLINICAL POSTING		MI 3.13, 1.9 HIV 1 (L)	PPr – Revision Class Revision Class MI 1.1 Manual checking and viva	
05 FEB 2026	THU	PA L-28 (7.1) Nomenclature, Characteristics of Benign & Malignant Neoplasm.	CLINICAL POSTING		L-26 26 PH 6.3 Drugs for Diarrhoea	SGL 14 MI 3.13, 1.9 HIV II (SGL)	AETCOM14 FMT-03 FMT AETCOM-3 FM 4.22 Oath in Medical Practice
06 FEB 2026	FRI	L-09 CM 8.1BEpidemiological characteristics and control measures including the use of essential laboratory tests at the primary care level for Faeco-oral diseases 2. Food poisoning, Amoebiasis, Ascariasis, Hookworm infection, Dracunculiasis.	CLINICAL POSTING		PA Seminar-5 Protein Calorie Manutrition, Obesity, Glycogen Storage Diseases	PH 6.4 Drugs for Constipation	PANDEMIC-08 CM MOD 2.2.4Emergence and Re-emergence of Microbes. Plenary of findings in the case studies and closure
7 FEB 2026	SAT	MI 1.1, 1.6 Dengue Fever (L)	SURGERY/ AETCOM		PH 6.5 Drugs for IBD/IBS	PA SGD 3.1 Lymphadenitis: Non-specific	Sports 17
08 FEBRUARY 2026 SUNDAY							
DAT E	DAY	9.-10.00AM	10-01PM	L	2.00-3.00PM	3.00PM–4.00PM	4.00-5.00PM
09 FEB 2026	MON	Su-15 Investigation of surgical patient chapter 8, 11,12 SU9.2.2	CLINICAL POSTING		PA L-29 (7.2) Molecular basis of cancer, self-sufficiency in growth signals – oncogenes, oncoproteins & cell growth.	PPr (4.1,12.3)Chronic Venous Congestion, Infarcts of Common Organs, Splenomegaly (Batch A) PH 10.4 Describe parts of a correct, rational, and legible prescription and write rational prescriptions for the provided condition. (examples of conditions to be used are given with other relevant competencies).	

DATE	DAY	9.-10.00AM	10-01PM	L	2.00-3.00PM	3.00PM-4.00PM	4.00-5.00PM
16 FEB 2026	MON	Su-16 Pre Intra & Post operative management SU10.1.1	CLINICAL POSTING ATCH 2024 P		PA L-31(7.4) Evasion of cell death. Limitless replication Potential Angiogenesis. Invasion and metastasis.	PPr (2.1)Infectious Disease - Rhinosporidiosis, Aspergillosis, Mycetoma Hydatid Cyst (Batch A)	
						PH 10.4 Describe parts of a correct, rational, and legible prescription and write rational prescriptions for the provided condition. (examples of conditions to be used are given with other relevant competencies).	
						MI 1.4, 11.1 Identification of GPC	
17 FEB 2026	TUE	L-29L-29PH 7.3 Drugs for Thyroid Disorders	CLINICAL POSTING		GM-17 IM 15.11 15.12 Develop document and present a treatment plan that includes fluid resuscitation, blood and blood component transfusion, and specific therapy for arresting blood loss Enumerate the indications for whole blood, component and platelet transfusion and describe the clinical features and management of a mismatched transfusion	PPr (2.1)Infectious Disease - Rhinosporidiosis, Aspergillosis, Mycetoma Hydatid Cyst (Batch C)	
						PH 10.4 Describe parts of a correct, rational, and legible prescription and write rational prescriptions for the provided condition. (examples of conditions to be used are given with other relevant competencies).	
						MI 1.4, 11.1 Identification of GPC	
18 FEB 2026	WED	OG-16 OG 13.3 LABOUR ANATOMY PHYSIOLOGY	CLINICAL POSTING		MI 3.10, 3.11 Lymphatic Filariasis (L)	PPr (2.1)Infectious Disease - Rhinosporidiosis, Aspergillosis, Mycetoma Hydatid Cyst (Batch B)	
						PH 10.4 Describe parts of a correct, rational, and legible prescription and write rational prescriptions for the provided condition. (examples of conditions to be used are given with other relevant competencies).	
						MI 1.4, 11.1 Identification of GPC	
19 FEB 2026	THU	PA L-32 (7.5) Evasion of immune surveillance, genomic instability	CLINICAL POSTING		L-30 PH 7.4 Anterior Pituitary Hormones	SGL 16 FM-3.3 Mechanical Injuries (Incision)	AETCOM 16 PA 05
							Aetcom-5 Module 2.4: Working in a health care team – “Tag along” session in hospital -I
20 FEB	FRI	L-07	CLINICAL		SDL-06 PH 7.5 Corticosteroids	PA Seminar 06- DIC & Vitamin	PANDEMIC-10 MI

2026		FM-3.3 Mechanical Injuries (Stab)	POSTING TUTE O			K deficiency & Rickets/Osteomalacia	PM 2.1 Contact Precautions
21 FEB 2026	SAT	MI 1.1, 1.6 Systemic Candidiasis, Systemic Mycoses (L)	PH EXTRA / REVISION CLASSESS PH 7.6 Androgens & drugs for Erectile Dysfunction	P	SDL-05CM8.1 Antimicrobial Resistance as Community Health Problem (Group Presentation)	PH 7.7 Contraceptives	Sports 19
DATE	DAY	9.-10.00AM	10- 01PM	L	2.00-3.00PM	3.00PM-4.00PM	4.00-5.00PM
22 FEBRUARY 2026 SUNDAY							
23 FEB 2026	MON	Su-17 Nutrition & fluid therapy SU12.1	CLINICAL POSTING		PA L-33 (7.6) Cancer- enabling inflammation, dysregulation of cancer- associated genes.	PPr (10.1) Benign Tumors - Leiomyoma, Lipoma, Squamous Papilloma, Capillary Hemangioma & Cavernous Hemangioma. (Batch A) PH 10.4 Describe parts of a correct, rational, and legible prescription and write rational prescriptions for the provided condition. (examples of conditions to be used are given with other relevant competencies). MI 1.4, 11.1 Identification of GNB	
24 FEB 2026	TUES	L-31 PH 7.8 Uterine stimulants & relaxants	CLINICAL POSTING		GM-18 IM 15.14, 15.15 15.16 Describe and enumerate the indications, pharmacology and side effects of pharmacotherapy of pressors used in the treatment of Upper GI bleed Describe and enumerate the indications, pharmacology and side effects of pharmacotherapy of acid peptic disease including helicobacter pylori Enumerate the indications for endoscopic interventions and surgery	PPr (10.1) Benign Tumors - Leiomyoma, Lipoma, Squamous Papilloma, Capillary Hemangioma & Cavernous Hemangioma. (Batch C) PH 10.4 Describe parts of a correct, rational, and legible prescription and write rational prescriptions for the provided condition. (examples of conditions to be used are given with other relevant competencies). MI 1.4, 11.1 Identification of GNB	

25 FEB 2026	WED	L-17 OG13.4 LABOUR MECHANISM -of normal labour	CLINICAL POSTING		MI 1.1, 1.6 Chikungunya, Ebola ,Marburg Disease (SGL)	PPr (10.1) Benign Tumors - Leiomyoma, Lipoma, Squamous Papilloma, Capillary Hemangioma & Cavernous Hemangioma. (Batch B)
						PH 10.4 Describe parts of a correct, rational, and legible prescription and write rational prescriptions for the provided condition. (examples of conditions to be used are given with other relevant competencies).
						MI 1.4, 11.1 Identification of GNB
26 FEB 2026	THU	PA L-34 (7.7) Molecular basis of multistep carcinogenesis, Carcinogenesis - agents and their cellular interaction. Chemical, direct and indirect acting, Radiation and microbial carcinogenesis.	CLINICAL POSTING		L-32PH 7.9 Drugs for Infertility	SGL 17 FM-3.3 Mechanical Injuries (Chop, Defense, Concealed, A.M. vs P.M. Injuries)
						AETCOM 17 PH-04 Module 2.2 Describe and discuss theroleofautonomyand sharedresponsibilityasa guiding principle in patient care. (2)
27 FEB 2026	FRI	L-11CM 8.1BEpidemiological characteristics and control measures including the use of essential laboratory tests at the primary care level for Faeco-oral diseases 6. Acute diarrheal disease, Cholera, Typhoid fever	CLINICAL POSTING		PA SGD 7.1,7.2Jaundice/ Hepatic failure/ Hepatitis	MI 4.1, 4.5 Food Poisoning (SGL)
						PANDEMIC-11 Module 2.5 Therapeutics strategies including new drug development
28 FEB 2026	SAT	MI 4.1 to 4.4 Gastrointestinal infection due to Enterobacteriaceae (SGL)	MI EXTRA / REVISION CLASSESS MI 4.1, 4.2, 4.4 Cholera (SGL) MI 4.1, 4.2, 4.4 compylobact or & H pylori,		PH 8.1, PH 8.2 General principles of Chemotherapy / Rational use of AMAS	PA Tutorial 4.1 CSF examination+ Meningitis V/B/F
						Sports 20

			Clostridium difficile (SGL)				
01 MARCH 2026 SUNDAY							
DATE	DAY	9.-10.00AM	10-01PM	L	2.00-3.00PM	3.00PM–4.00PM	4.00-5.00PM
02 MAR 2026	MON	SU-18 Nutrition & fluid therapy SU12.2 & SU 12.3	CLINICAL POSTING		PA L-35 (7.8) Clinical Aspects- Clinical manifestation Grading & Staging Lab diagnosis Tumor marker	PPr (24.1,26.1)Malignant Tumors (I)- SCC, Adenocarcinoma, BCC (Batch A)	
						Revision Class	
						MI 3.1 to3.4 CBL on BSI	
03 MAR 2026	TUES	L-33 PH 8.3 Sulphonamides	CLINICAL POSTING		GM-19 IM 9.1 , 9.2 , 9.7 9.8 Define, describe and classify anemia based on red blood cell size and reticulocyte count Describe and discuss the morphological characteristics, aetiology, prevalence of each of the causes of anemia Describe and discuss the meaning and utility of various components of the hemogram Describe, discuss the various tests for iron deficiency	PPr (24.1,26.1)Malignant Tumors (I)- SCC, Adenocarcinoma, BCC (Batch C)	
						Revision Class	
						MI 3.1 to3.4 CBL on BSI	
04 MARCH 2026 HOLI							
05 MAR 2026	THUR	L-36 (PA8.1,8.2) Principles and mechanisms involved in immunity. Hypersensitivity reactions	CLINICAL POSTING		L-34 PH 8.3 Quinolones	SGL 18 FM 3.4 Medico Legal Aspects of Injuries	AETCOM 18 FMT-04 FM 4.23 Modified Declaration of Geneva
06 MAR 2026	FRI	L-08 FM 3.4 Medico Legal Aspects of Injuries	CLINICAL POSTING		SDL-07 MI 4.1, 4.2, 4.4 Viral gastroenteritis	PH 8.3 Beta lactams -I	PANDEMIC-12 MOD 2.4.1 Describe the process of vaccine development.

07 MAR 2026	SAT	MI 4.1 to 4.4 Intestinal amoebiasis (L)	SURGERY/ AETCOM		SDL-06 CM 8.1 India is ready for elimination of tuberculosis by 2025 (Debate)	PA SDL Quiz – Case discussion	Sports 21
DATE	DAY	9.-10.00AM	10-01PM	L	2.00-3.00PM	3.00PM–4.00PM	4.00-5.00PM
8 MARCH 2026 SUNDAY							
09 MAR 2026	MON	SU-19 Introduction, curriculum & Assessment methods SU0.0.0	CLINICAL POSTING		L-37 (PA8.3,8.4) Autoimmunediseases. SystemicLupus Erythematosus	PPr (27.1)Malignant Tumors (II)- Malignant Melanoma & Lymph Node Metastatic Deposits- SCC /Adenocarcinoma (Batch A)	
						PH 10.9 Calculate the dosage of drugs for an individual patient, including children, elderly, pregnant and lactating woman, and patients with renal or hepatic dysfunction.	
						MI 4.1, 1.4 Examination of stool	
10 MAR 2026	TUE	L-35 PH 8.3 Beta lactams -II	CLINICAL POSTING		GM -20 IM 9.11 , 9.12 9.17 ,S 9.18 Describe the indications and interpret the results of a bone marrow aspirations and biopsy Describe, developed a diagnostic plan to determine the aetiology of anemia Describe the indications for blood transfusion and the appropriate use of blood components Describe the precautions required necessary when performing a blood transfusion	PPr (27.1)Malignant Tumors (II)- Malignant Melanoma & Lymph Node Metastatic Deposits- SCC /Adenocarcinoma (Batch C)	
						PH 10.9 Calculate the dosage of drugs for an individual patient, including children, elderly, pregnant and lactating woman, and patients with renal or hepatic dysfunction.	
						MI 4.1, 1.4 Examination of stool	
11 MAR 2026	WED	L -18 OG 13.4 Clinical course and management of first stage of labour	CLINICAL POSTING		MI 4.1 to 4.4 Giardiasis, Opportunistic parasite of GI (L)	PPr (27.1)Malignant Tumors (II)- Malignant Melanoma & Lymph Node Metastatic Deposits- SCC /Adenocarcinoma (Batch B)	
						PH 10.9 Calculate the dosage of drugs for an individual patient, including children, elderly, pregnant and lactating woman, and patients with renal or hepatic dysfunction.	
						MI 4.1, 1.4 Examination of stool	

12 MAR 2026	THU	L-38 (PA8.5) AIDS: Epidemiology,etiopathogenesis.	CLINICAL POSTING		L-36 PH 8.3 Macrolides	SGL 19 FM 3.5, 3.6 Medico Legal Aspects of Injuries	AETCOM 19 PMI06
							2.2 E Describe and discuss the role of justice as a guiding principle in patient care
13 MAR 2026	FRI	L-12 CM 8.1C Epidemiological characteristics and control measures including the use of essential laboratory tests at the primary care level for zoonotic diseases 1. Rabies	CLINICAL POSTING		MI 4.1 to 4.4, 3.10 Intestinal Helminths Tenia solium , F. hepatica (L)	PA Seminar 07 – Blood Transfusion / Bombay blood group / Autologous blood Transfusion	SDL-03 FM 3.7 Medico Legal Aspects of Injuries
14 MAR 2026	SAT	MI 4.1 to 4.4, 3.10 Intestinal Helminths D. latum, H.nana (L)	MI EXTRA / REVISION CLASSESS MI 4.1 to 4.4, 3.10 Intestinal nematodes : Trichuris, Enterobius , Strongyloi des (SGL)		PA SGD 3.2 Portal hypertension/NASH	PH 8.3 Tetracyclines	Sports 22
DATE	DAY	9.-10.00AM	10-01PM	L	2.00-3.00PM	3.00PM–4.00PM	4.00-5.00PM
15 MARCH 2026 SUNDAY							
16 MAR 2026	MON	SU-20 PCT & FEED BACK SU 0.0.0	CLINICAL POSTING		L-39 (PA21.1) Vascular structure & function Hypertensive Heart disease.	PPr(12.1,12.2,13.1)Reactive Lymphadenitis, Hodgkin lymphoma, Multiple myeloma. (Batch A)	
						PH 10.13 Demonstrate how to optimize interaction with pharmaceutical representative/media to get/disseminate authentic information on drug.	
						Manual checking and viva	
17 MAR 2026	TUE	-37PH 8.3 Aminoglycosides	CLINICAL POSTING		G-21 IM 25.1 25.2 25.8 Describe and discuss the response and the influence of host. immune status, risk factors and comorbidities on zoonotic diseases (e.g. Leptospirosis.Rabies) and non-febrile infectious disease (e.g. Tetanus) Discuss and describe the common	PPr(12.1,12.2,13.1)Reactive Lymphadenitis, Hodgkin lymphoma, Multiple myeloma. (Batch C)	
						PH 10.13 Demonstrate how to optimize interaction with pharmaceutical representative/media to get/disseminate authentic information on drug.	
						Manual checking and viva	

					causes, pathophysiology and manifestations of these diseases Enumerate the indications for use of newer techniques in the diagnosis of these infections		
18 MAR 2026	WED	L -19 OG 13.4 Clinical course and management of second stage of labour	CLINICAL POSTING		MI 4.1 to 4.4, 3.10 Intestinal nematodes: hookworm (L)	PPr(12.1,12.2,13.1)Reactive Lymphadenitis, Hodgkin lymphoma, Multiple myeloma. (Batch B)	
						PH 10.13 Demonstrate how to optimize interaction with pharmaceutical representative/media to get/disseminate authentic information on drug.	
						Manual checking and viva	
19 MAR 2026	THU	L-40 (PA21.2) Atherosclerosis.	CLINICAL POSTING		1-38PH 8.4 Drugs for UTI & STD's	SGL 20 FM-8.1 General Toxicology	AETCOM20 PH-05
							Module 2.2 Describe and discuss the role of beneficence of a guiding principle in patient care. (3)
20 MAR 2026	FRI	L-09 FM-8.2 General Toxicology	CLINICAL POSTING		PA Tutorial 11.2 IHC/ Molecular Cytogenetic analysis for diagnosis of Cancer	PH 8.5 Drugs for TB -I	PANDEMIC -13 MI
							PM 2.3 Sample collection for viral infections
21/03/2026 EID-UL FITAR							
SUNDAY 22/03/2026							
DATE	DAY	9.-10.00AM	10-01PM	L	2.00-3.00PM	3.00PM-4.00PM	4.00-5.00PM
23 MARC 2026	MON	L-41 (PA21.3) Cardiac structure: Heart failure	CLINICAL POSTING		PH 8.5 Drugs for TB -II	PPr (16.1)GIT – Gastric ulcer, Gastric adenocarcinoma, Gastric signet ring cell carcinoma, Benign Polyp (Batch A)	
						PH 10.13 Demonstrate how to optimize interaction with pharmaceutical representative/media to get/disseminate authentic information on drug.	
						MI 4.1 CBL on GI infections	
24 MARCH 2026	TUES	L-39PH 8.6 Drugs for Leprosy	CLINICAL POSTING		L-42 (PA21.4) Ischemic Heart Disease	PPr (16.1)GIT – Gastric ulcer, Gastric adenocarcinoma, Gastric signet ring cell carcinoma, Benign Polyp (Batch C)	
						PH 10.13 Demonstrate how to optimize interaction with pharmaceutical representative/media to get/disseminate authentic information on drug.	

					MI 4.1 CBL on GI infections	
25 MAR 2026	WED	L -20 OG 13.4 Clinical course and management of third stage of labour	CLINICAL POSTING		MI 4.1 to 4.4, 3.10 Intestinal nematodes: Ascaris (L)	PPr (16.1)GIT – Gastric ulcer, Gastric adenocarcinoma, Gastric signet ring cell carcinoma, Benign Polyp (Batch B) PH 10.13 Demonstrate how to optimize interaction with pharmaceutical representative/media to get/disseminate authentic information on drug.
					MI 4.1 CBL on GI infections	
26 MAR 2026	THUR	L-43 (PA21.5) Rheumatic Heart disease, Infective Endocarditis.	CLINICAL POSTING		L-40 PH 8.7 Drugs for Amoebiasis	SGL 21 FM-8.3 General Toxicology AETCOM21 PA-06 Aetcom-6 Module 2.4: Working in a health care team – “Tag along” session in hospital-II
27 MAR 2026	FRI	L-13CM 8.1C Epidemiological characteristics and control measures including the use of essential laboratory tests at the primary care level for zoonotic diseases 2. Yellow fever & Japanese encephalitis	CLINICAL POSTING		SDL-08 MI 4.7, 4.8, 4.9 Viral Hepatitis I	PA SDL Library Assignment/ Museum visit PANDEMIC-14 PH Module 2.5 Therapeutics strategies including new drug development (2)
28 MAR 2026	SAT	MI 4.7, 4.8, 4.9 Viral Hepatitis II (SGL)	PA Seminar 08-TTI / Hemolytic disease of New born / Hydrops Fetalis / TRALI (Transfusion-related Acute Lung Injury)		PH 8.7 Drugs for Kala-azar	MI 4.7, 4.8, 4.9 Viral Hepatitis III including yellow fever (SGL) G.M 20 IM 23.1, 23.2, 23.4 Discuss and describe the methods of nutritional assessment in an adult and calculation of caloric requirements during illnesses Discuss and describe the causes and consequences of protein caloric malnutrition in the hospital. Enumerate the indications for enteral and parenteral nutrition in critically ill patients
29 MARCH 2026 SUNDAY						
DATE	DAY	9.-10.00AM	10-01PM	L	2.00-3.00PM	3.00PM-4.00PM 4.00-5.00PM
30 MAR	MON	L-44 (PA21.6, 21.7)	CLINICAL POSTING		PH 8.7 Drugs for Malaria	PPr (17.1)Hepatobiliary system - Fatty Liver, Liver Cirrhosis (Batch A)

2026		Cardiomyopathies, Pericarditis, HDCM				PH 10.15 Describe methods to improve adherence to treatment and motivate patients with chronic disease to adhere to the prescribed Pharmacotherapy.	
						MI 1.4, 11.1 Identification of GNB/GPC: revision	
31 MAR 2026	TUES	L-41 PH 8.7 Drugs for Filariasis	CLINICAL POSTING		L-45 (PA20.1) Chronic obstructive pulmonary disease.	PPr (17.1) Hepatobiliary system - Fatty Liver, Liver Cirrhosis (Batch C)	
						PH 10.15 Describe methods to improve adherence to treatment and motivate patients with chronic disease to adhere to the prescribed Pharmacotherapy.	
						MI 1.4, 11.1 Identification of GNB/GPC: revision	
01 APR 2026	WED	OG-20	CLINICAL POSTING		MI 1.1, 4.1, 9.1 Echinococcus (SGL)	PPr (17.1) Hepatobiliary system - Fatty Liver, Liver Cirrhosis (Batch B)	
						PH 10.15 Describe methods to improve adherence to treatment and motivate patients with chronic disease to adhere to the prescribed Pharmacotherapy.	
						MI 1.4, 11.1 Identification of GNB/GPC: revision	
02 APR 2026	THUR	L-46 (PA20.2) Occupational lung disorders.	CLINICAL POSTING		L-42 PH 8.8 Drugs for Fungal infections	SGL 22 FM-8.4 General Toxicology	AETCOM 22 MI 07
							2.3 Describe and discuss the role of justice as a guiding principle in patient care
03 APR 2026	FRI	L-10 FM-8.5 General Toxicology	CLINICAL POSTING		SDL-08 MI 1.1, 4.1, 9.1 Amoebic liver abscess, F. hepatica	PA SGD Wilson's disease / Hemochromatosis / Alpha-1 Antitrypsin	PANDEMIC-15
							MOD 2.4.2 Describe the role of vaccines in disease control and eradication.
04 APR 2026	SAT	MI 5.2, 5.3 Staphylococcal infection (SGL)	SURGERY/AETCOM		PA Tutorial 4.4 Tumor Markers	PH 8.9 Drugs for Helminthiasis	SPORTS24
05 APRIL 2026 SUNDAY							
DATE	DAY	9.-10.00AM	10-01PM	L	2.00-3.00PM	3.00PM-4.00PM	4.00-5.00PM
06 APR 2026	MON	L-47 (PA20.3) Tuberculosis (T.B)	CLINICAL POSTING		L-43 PH 8.10 Drugs for Viral infections	PPr (18.1) Thyroid disorders- Colloid Goitre, Hashimoto's, Follicular Adenoma, PTC, Medullary Thyroid Carcinoma (Batch A)	
						PH 10.15 Describe methods to improve adherence to treatment and motivate patients with chronic disease to adhere to the prescribed Pharmacotherapy.	

						MI 1.1, 4.7, 4.8, 4.9 CBL on hepatobiliary infections
07 APR 2026	TUES	L-44PH 8.10 Drugs for HIV	CLINICAL POSTING		SGL 23 FM-8.6 General Toxicology	PPr (18.1)Thyroid disorders- Colloid Goitre, Hashimoto's, Follicular Adenoma, PTC, Medullary Thyroid Carcinoma (Batch C)
						PH 10.15 Describe methods to improve adherence to treatment and motivate patients with chronic disease to adhere to the prescribed Pharmacotherapy.
						MI 1.1, 4.7, 4.8, 4.9 CBL on hepatobiliary infections
08 APR 2026	WED	L-48 (PA20.4) Tumors of lung and pleura.	CLINICAL POSTING		MI 5.2, 5.3 Streptococcal infection (L)	PPr (18.1)Thyroid disorders- Colloid Goitre, Hashimoto's, Follicular Adenoma, PTC, Medullary Thyroid Carcinoma (Batch B)
						PH 10.15 Describe methods to improve adherence to treatment and motivate patients with chronic disease to adhere to the prescribed Pharmacotherapy.
						MI 1.1, 4.7, 4.8, 4.9 CBL on hepatobiliary infections
09 APR 2026	THUR	L 45PH 8.11 Anti-cancer Drugs - I	CLINICAL POSTING		L-49PA (18.1) GIT – Oesophagus.	SDL-03 FM-8.7 General Toxicology
						AETCOM23 PH-06 Module 2.2 Describe and discuss the role of a physician in the healthcare system. (4)
10 APR 2026	FRI	L-14CM 8.1C Epidemiological characteristics and control measures including the use of essential laboratory tests at the primary care level for zoonotic diseases 3. Plague and Leptospirosis	CLINICAL POSTING		PA SDL - Gross & Instrument	MI 5.1 Gas Gangrene (L)
						PANDEMIC-16 GM
11 APR 2026	SAT	MI 5.5 Leprosy (L)	MI EXTRA/ REVISION CLASSES MI 5.2, 5.3, 5.4 HSV, Measles, Small pox rubella and others (SGL),		PH 8.11 Anti-cancer Drugs – II	PA Seminar 09 - Cholecystitis with cholelithiasis / Gall bladder carcinoma / Primary biliary cirrhosis
12 APRIL 2026 SUNDAY						
DATE	DAY	9.-10.00AM	10-01PM	L	2.00-3.00PM	3.00PM–4.00PM
13 APR	MON	L-50PA (18.2)	CLINICAL		L-46PH 9.1 Immunomodulators	PPr (23.1)Breast- Fibroadenoma of Breast, IDC, Phyllodes

2026		GIT – Stomach I: Peptic ulcer.	POSTING		Tumour(Batch A)	
					PH 10.5 Identify and apply the legal and ethical regulation of prescribing drugs especially when prescribing for controlled drugs, off-label medicines, and prescribing for self, close family and friends	
					MI 5.1, 5.2, 5.3, 5.4, 5.5 CBL on skin and soft tissue	
14 APR 2026	TUES	L-47PH 9.2 Management of common drug poisonings etc.	CLINICAL POSTING	SGL-24 FM-8.8 General Toxicology	PPr (23.1)Breast- Fibroadenoma of Breast, IDC, Phyllodes Tumour(Batch C)	
					PH 10.5 Identify and apply the legal and ethical regulation of prescribing drugs especially when prescribing for controlled drugs, off-label medicines, and prescribing for self, close family and friends	
					MI 5.1, 5.2, 5.3, 5.4, 5.5 CBL on skin and soft tissue	
15 APR 2026	WED	L-51PA (18.3) GIT – Stomach II: Tumours.	CLINICAL POSTING	MI 5.2, 5.3 Parasitic infection of skin and soft tissue (SGL)	PPr (23.1)Breast- Fibroadenoma of Breast, IDC, Phyllodes Tumour(Batch B)	
					PH 10.5 Identify and apply the legal and ethical regulation of prescribing drugs especially when prescribing for controlled drugs, off-label medicines, and prescribing for self, close family and friends	
					MI 5.1, 5.2, 5.3, 5.4, 5.5 CBL on skin and soft tissue	
16 APR 2026	THUR	L-48PH 9.3 Chelating agents + Make of heavy metal poisoning	CLINICAL POSTING	L-52PA (18.4) GIT – Intestine I: Ulcerative lesions, Idiopathic inflammatory bowel disease.	SDL-04 FM-3.9 Firearm Injury	AETCOM 24 PA-07
						Aetcom-7 Module 2.4: Working in a health care team – Small group discussion session -I
17 APR 2026	FRI	L-11 FM-3.10 Firearm Injury	CLINICAL POSTING	SDL-09SDL-09PH 9.6 Drugs for various skin disorders	PA SGD 7.1 Chronic renal failure + Acute Renal failure	PANDEMIC-17
						PM 2.3 Microbial diagnosis for pandemic diseases
18 APR 2026	SAT	MI 5.2, 5.3 Larva migrans: Cutaneous and visceral (L)	PH EXTRA/ REVISION CLASSESS PH 9.7 Drugs for Glaucoma	PA Tutorial 9.2 Pathogenesis of Covid-19 - Cytokine storm, Laboratory Markers, Hematological indices, Coagulation Profile	MI 5.2, 5.3 Superficial fungal infections (SGL)	SPORTS 26

19 APRIL 2026 SUNDAY

DATE	DAY	9.-10.00AM	10-01PM	L	2.00-3.00PM	3.00PM-4.00PM	4.00-5.00PM
20 APR 2026	MON	L-53 PA (18.5) GIT – Intestine II: TumoursoflowerGastrointestinalTract.	CLINICAL POSTING		REVISION CLASESS	PPr (22.1)MGT- BPH, Seminoma, Prostate Adenocarcinoma (Batch A)	
						PH 10.6 Perform a critical appraisal of a given prescription and suggest waysto improve it.	
						Manual checking and viva	
21 APR 2026	TUES	REVISION CLASESS	CLINICAL POSTING		PA – Revision Class	PPr (22.1)MGT- BPH, Seminoma, Prostate Adenocarcinoma (Batch C)	
						PH 10.6 Perform a critical appraisal of a given prescription and suggest waysto improve it.	
						Manual checking and viva	
22 APR 2026	WED	L-54 PA (18.6) Oral cavity & Salivary gland.	CLINICAL POSTING		MI 5.2, 5.3 Subcutaneous mycosis (L)	PPr (22.1)MGT- BPH, Seminoma, Prostate Adenocarcinoma (Batch B)	
						PH 10.6 Perform a critical appraisal of a given prescription and suggest waysto improve it.	
						Manual checking and viva	
23 APR 2026	THU	L-51REVISION CLASESS	CLINICAL POSTING		L-55 PA (3.1) Amyloidosis.	FM-3.12 Road Traffic Injuries	AETCOM 25 MI-08
							2.3 Describe and discuss the role of justice as a guiding principle in patient care
24 APR 2026	FRI	FM-3.12 Road Traffic Injuries	CLINICAL POSTING		MI 5.2, 5.3 Opportunistic mycoses of skin and soft tissue	AETCOM 26 PH 08	PANDEMIC-18 MI
						1.Module 2.2Describeanddiscuss the role of justice as a guidingprinciplein patient care. (5)	PM 2.3 Serologic tests for viral diseases
25 APR 2026	SAT	MI 7.1, 7.4 Bacterial pharyngitis: streptococcal pharyngitis and others (L)	MI EXTRA/ REVISION CLASESS MI 7.1, 7.4 Lobar pneumonia: streptococcus pneumonia (L) MI 7.2, 7.3, 7.5 Lobar pneumonia:		INTEGRATIONREVISION CLASESS	Sports 27	



			Haemophilus influenzae and others (SGL)				
DATE	DAY	9.-10.00AM	10-01PM	L	2.00-3.00PM	3.00PM–4.00PM	4.00-5.00PM
26 APR 2026 SUNDAY							
27 APR 2026	MON	L-56 PA (19.1) Viralhepatitis.	CLINICAL POSTING		REVISION CLASESS	PPr (21.1)FGT- Serous Cystadenoma, Mucinous Cystadenoma, Teratoma & miscellaneous ovarian carcinoma. (Batch A)	
						PH 10.7 Describe Pharmacogenomics and Pharmacoeconomics and manage genomic & economic issues in drug use and find out the price of given medications .	
						Manual checking and viva	
28 APR 2026	TUES	L-52REVISION CLASESS	CLINICAL POSTING		FM-3.10 Blast Injuries	PPr (21.1)FGT- Serous Cystadenoma, Mucinous Cystadenoma, Teratoma & miscellaneous ovarian carcinoma. (Batch C)	
						PH 10.7 Describe Pharmacogenomics and Pharmacoeconomics and manage genomic & economic issues in drug use and find out the price of given medications .	
						Manual checking and viva	
29 APR 2026	WED	L-57 PA (19.2) Alcoholic liverdisease	CLINICAL POSTING		MI 7.2, 7.5 Tuberculosis I (L)	PPr (21.1)FGT- Serous Cystadenoma, Mucinous Cystadenoma, Teratoma & miscellaneous ovarian carcinoma. (Batch B)	
						PH 10.7 Describe Pharmacogenomics and Pharmacoeconomics and manage genomic & economic issues in drug use and find out the price of given medications .	
						Manual checking and viva	
30 APR 2026	THUR	54REVISION CLASESS	CLINICAL POSTING		L-58 PA (19.3) Cirrhosis.	FM-3.10 Blast Injuries	AETCOM 27 MI09
							2.5 Identify, discuss and defend medico-legal, socio-cultural and ethical issues as it pertains to patient autonomy, patient rights and shared responsibility in health care
01 MAY 2026 HOLIDAY BUDDHPURNIMA							
2 ND Terminal Examination THEORY EXAM							
DATE		DAY		SUBJECTS		TIME	



02/05/2026	SATURDAY	GEN. MEDICINE	10 AM – 01 PM
03 MAY 2026 SUNDAY			
04/05/2026	MONDAY	GEN. SURGERY	10 AM – 01 PM
05/05/2026	TUESDAY	OBGYN	10 AM – 01 PM
06/05/2026	WEDNESDAY	PATHOLOGY	10 AM – 01 PM
07/05/2026	THURSDAY	PHARMACOLOGY	10 AM – 01 PM
08/05/2026	FRIDAY	MICROBIOLOGY	10 AM – 01 PM
09/05/2026	SATURDAY	COMMUNITY MEDICINE	10 AM – 01 PM
10 MAY 2026 SUNDAY			
11/05/2026	MONDAY	FORENSIC MEDICINE	10 AM – 01 PM

2ND TERMINAL PRACTICAL EXAMINATION

DATE	DAYS	PATHOLOGY	PHARMACOLOGY	MICROBIOLOGY	COMMUNITY MEDICINE	FORENSIC MEDICINE
12/05/2026	TUESDAY	BATCH - A (1-30)	BATCH- B (31-60)	BATCH -C (61-90)	BATCH - D (91-120)	BATCH -E (121-150 & 81 A)
13/05/2026	WEDNESDAY	BATCH -E (121-150 & 81 A)	BATCH - A (1-30)	BATCH- B (31-60)	BATCH -C (61-90)	BATCH - D (91-120)
14/05/2026	THURSDAY	BATCH - D (91-120)	BATCH -E (121-150 & 81 A)	BATCH - A (1-30)	BATCH- B (31-60)	BATCH -C (61-90)
15/05/2026	FRIDAY	BATCH -C (61-90)	BATCH - D (91-120)	BATCH -E (121-150 & 81 A)	BATCH - A (1-30)	BATCH- B (31-60)



16/05/2026	SATURDAY	BATCH- B (31-60)	BATCH -C (61-90)	BATCH - D (91-120)	BATCH -E (121-150 & 81 A)	BATCH - A (1-30)
------------	----------	------------------	------------------	--------------------	---------------------------	------------------

Note:- Practical/Clinical Examination for subject taught in more than one phase will be conducted in the form of mandatorily ward leaving at the end of the session.

18 MAY TO 30 MAY 2026 SUMMAR VACATION

31 MAY 2026 SUNDAY

DATE	DAY	9.-10.00AM	10-01PM	L	2.00-3.00PM	3.00PM-4.00PM	4.00-5.00PM
01 JUNE 2026	MON	L-59 PA (19.4) Hepatocellular carcinoma	CLINICAL POSTING		55REVISION CLASESS	PPr (19.1)Miscellaneous- Wilm's Tumor, Neuroblastoma, Pleomophic Adenoma (Batch A)	
						PH 10.8 Describe essential medicines, Fixed dose combination, Over the counter drugs and explain steps to choose essential medicines.	
						Manual checking and viva	
02 JUNE 2026	TUES	L-56REVISION CLASESS	CLINICAL POSTING		SGL FM 7.1 Regional Injuries (Skull Fractures)	PPr (19.1)Miscellaneous- Wilm's Tumor, Neuroblastoma, Pleomophic Adenoma(Batch C)	
						PH 10.8 Describe essential medicines, Fixed dose combination, Over the counter drugs and explain steps to choose essential medicines.	
						Manual checking and viva	
03 JUNE 2026	WED	L-60 PA (19.5) Gall bladder (Cholelithiasis, cholecystitis & Tumours)	CLINICAL POSTING		MI 7.2, 7.5 Tuberculosis II (L)	PPr (19.1)Miscellaneous- Wilm's Tumor, Neuroblastoma, Pleomophic Adenoma (Batch B)	
						PH 10.8 Describe essential medicines, Fixed dose combination, Over the counter drugs and explain steps to choose essential medicines.	
						Manual checking and viva	
04 JUNE 2026	THUR	57REVISION CLASESS	CLINICAL POSTING		L-61 PA (22.1) Normal histology ofthe kidney & Renalfailure.	SDL-08 FM 7.1 Regional Injuries (Intracranial Hemorrhages)	AETCOM 29 PA-09
							Aetcom-8 Module 2.4: Working in a health care team – Small group discussion session -II

05 JUNE 2026	FRI	L-16CM 8.1C Epidemiological characteristics and control measures including the use of essential laboratory tests at the primary care level for zoonotic diseases 1. Brucellosis, Human Salmonellosis	CLINICAL POSTING		SDL-09 MI 7.1 to 7.5 Influenza and paraenfluenzae (SGL)	INTEGRATION REVISION CLASESS	 PANDEMIC-20 MOD 2.4.4 Describe the importance of routine vaccination during pandemics.
06 JUNE 2026	SAT	SDL-09 MI 7.1 to 7.5 Mumps, Coronavirus	SURGERY/ AETCOM		SDL-08 CM 1.1 Preventive medicine is more important than curative medicine (Debate)	SPORTS 29	
07 JUNE 2026 SUNDAY							
DATE	DAY	9.-10.00AM	10-01PM	L	2.00-3.00PM	3.00PM-4.00PM	4.00-5.00PM
08 JUNE 2026	MON	L-62 PA (22.2) Criteria,etiology,systemicmanifestationsandinvestigations.	CLINICAL POSTING		58REVISION CLASESS	PPr (19.1)Miscellaneous- Wilm’s Tumor, Neuroblastoma, Pleomophic Adenoma (Batch A)	
						PH 10.10 Identify when therapeutic drug monitoring is considered for a particular patient, determine timing of sampling and calculate revised dose.	
						MI 1.4, 1.10 Staining methods (G/S staining): DOAP revision	
09 JUNE 2026	TUES	L-59REVISION CLASESS	CLINICAL POSTING		SGL 28 FM 7.1 Regional Injuries (Spine & Spinal cord, Heart, Liver, Other Regions)	PPr (19.1)Miscellaneous- Wilm’s Tumor, Neuroblastoma, Pleomophic Adenoma(Batch C)	
						PH 10.10 Identify when therapeutic drug monitoring is considered for a particular patient, determine timing of sampling and calculate revised dose.	
						MI 1.4, 1.10 Staining methods (G/S staining): DOAP revision	
10 JUNE 2026	WED	L-63 PA (22.3) Glomerulonephritis.	CLINICAL POSTING		MI 7.1 to 7.5 Parasitic and fungal infections of respiratory tract (L)	PPr (19.1)Miscellaneous- Wilm’s Tumor, Neuroblastoma, Pleomophic Adenoma (Batch B)	
						PH 10.10 Identify when therapeutic drug monitoring is considered for a particular patient, determine timing of sampling and calculate revised dose.	
						MI 1.4, 1.10 Staining methods (G/S staining): DOAP revision	
11 JUNE 2026	THUR	60REVISION CLASESS	CLINICAL POSTING		L-64 PA (22.4) Pyelonephritisandinterstitialnephritis.	SGL 29 FM 2.24 Thermal Injuries	
						AETCOM 30 PH-07 Module 2.3 Describe and discuss the roleofjusticeasaguiding principle in patient care. (6)	

12 JUNE 2026	FRI	L-17CM 8.1C Epidemiological characteristics and control measures including the use of essential laboratory tests at the primary care level for zoonotic diseases Rickettsia and parasitic Zoonotic diseases	CLINICAL POSTING		SDLREVISION CLASESS	PA SDL – Case discussion- (CVS+MGT) case discussion (2+2)	 PANDEMIC-21 2.3 performance parameters for viral infections
13 JUNE 2026	SAT	MI 6.1, 6.3 Acute and chronic bacterial Meningitis II (L)	MI EXTRA/ REVISION CLASESS MI 5.1 Tetanus (L) MI 6.1, 6.2 Poliomyelitis (L)		SDL-09 CM 8.1 Epidemiology of Communicable Diseases (Quiz)	SPORTS 30	
14 JUNE 2026 SUNDAY							
DATE	DAY	9.-10.00AM	10-01PM	L	2.00-3.00PM	3.00PM–4.00PM	4.00-5.00PM
15 JUNE 2026	MON	L-65 PA (22.5) Acute TubularNecrosis.	CLINICAL POSTING		61REVISION CLASESS	PPr (20.1)Bone tumors - Osteoclastoma, Osteogenic Sarcoma & Ewing’s Sarcoma (Batch A)	
						PH 10.11 Identify and apply drug regulations principles, acts, and legal aspects related of drug discovery and clinical use.	
						MI 7.1, 7.2, 7.3 CBL on RTI	
16 JUNE 2026	TUES	L-62REVISION CLASESS	CLINICAL POSTING		SGL 30 FM 2.25 Thermal Injuries	PPr (20.1)Bone tumors - Osteoclastoma, Osteogenic Sarcoma & Ewing’s Sarcoma (Batch C)	
						PH 10.11 Identify and apply drug regulations principles, acts, and legal aspects related of drug discovery and clinical use.	
						MI 7.1, 7.2, 7.3 CBL on RTI	
17 JUNE 2026	WED	L-66 PA (22.6) Nephrolithiasisandobstructivenephro pathy.	CLINICAL POSTING		MI 6.2 Rabies (L)	PPr (20.1)Bone tumors - Osteoclastoma, Osteogenic Sarcoma & Ewing’s Sarcoma (Batch B)	
						PH 10.11 Identify and apply drug regulations principles, acts, and legal aspects related of drug discovery and clinical use.	
						MI 7.1, 7.2, 7.3 CBL on RTI	
18 JUNE 2026	THUR	63REVISION CLASESS	CLINICAL POSTING		L-67 PA (22.7, 22.8) Tumors of kidney and pelvis. Urinary bladder: cystitis and carcinoma	INTEGRATION MI 6.2 Japanese Encephalitis (SGL)	AETCOM 31 PH-08 Module 2.5 Identify, discuss, and defend medico-legal, socio-cultural, and ethical issues as it pertains to patient

							 
							autonomy, patientrights,andshared responsibility in health Care. (7)
19 JUNE 2026	FRI	L-18 CM 8.1D Epidemiological characteristics and control measures including the use of essential laboratory tests at the primary care level for Arthropod borne diseases Malaria and Zika Virus	CLINICAL POSTING		INTEGRATIONREVISION CLASESS	AETCOM 32 MI 10	PANDEMIC-22 PH
						2.5 Identify, discuss and defend medico-legal, socio-cultural and ethical issues as it pertains to patient autonomy, patient rights and shared responsibility in health care	Module 2.5 Therapeutics strategies including new drug development (3)
20 JUNE 2026	SAT	MI 6.2 Nipah, handra and slow virus disease (L)	PA EXTRA/ REVISION CLASESS		INTEGRATIONREVISION CLASESS	SPORTS 31	
21 JUNE 2026 SUNDAY							
DATE	DAY	9.-10.00AM	10-01PM	L	2.00-3.00PM	3.00PM–4.00PM	4.00-5.00PM
22 JUNE 2026	MON	L-68 PA (23.1) Testicular tumors	CLINICAL POSTING		64REVISION CLASESS	PPr (25.1) Renal system- CPN, RCC (Batch A)	
						PH 10.12 Describe overview of drug development including phases of clinical practice & reflect on the role of research in developing new drug.	
						MI 1.4, 1.10 Staining methods (ZN staining): DOAP revision	
23 JUNE 2026	TUES	L-65REVISION CLASESS	CLINICAL POSTING		SGL 31 FM 2.25 Thermal Injuries	PPr (25.1) Renal system- CPN, RCC (Batch C)	
						PH 10.12 Describe overview of drug development including phases of clinical practice & reflect on the role of research in developing new drug.	
						MI 1.4, 1.10 Staining methods (ZN staining): DOAP revision	
24 JUNE 2026	WED	L-69 PA (23.2, 23.3) Prostate: carcinoma, BPH.	CLINICAL POSTING		MI 6.1, 6.2, 6.3 Fungal infections of CNS (SGL)	PPr (25.1) Renal system- CPN, RCC (Batch B)	
						PH 10.12 Describe overview of drug development including phases of clinical practice & reflect on the role of research in developing new drug.	
						MI 1.4, 1.10 Staining methods (ZN staining): DOAP revision	
25 JUNE	THUR	66REVISION CLASESS	CLINICAL		L-70 PA (24.1,24.2)	INTEGRATION 04	AETCOM 33 PA-10

															
2026			POSTING		Diseasesofcervix (cervicitis etc.); Carcinoma of the cervix	MI 6.1, 6.2, 6.3 Parasitic infections of CNS	Aetcom-9 Module 2.6: Bioethics continued: Case studies on autonomy and decision making – Introduction of case.								
26 JUNE 2026	FRI	L-19CM 8.1D Epidemiological characteristics and control measures including the use of essential laboratory tests at the primary care level for Arthropod borne diseases Dengue and Filariasis	CLINICAL POSTING		SDL MI 8.1, 8.4 Infective syndromes of urinary tract I	AETCOM -34 PH 09	PANDEMIC-23 GM								
						REVISION CLASESS									
27 JUNE 2026	SAT	MI 8.1, 8.4 Infective syndromes of urinary tract II (SGL)	PH EXTRA/ REVISION CLASESS		SDL-10 CM 8.1 Epidemiology of Communicable Diseases (Quiz)	SPORTS 32									
28 JUNE 2026 SUNDAY															
DATE	DAY	9.-10.00AM	10-01PM	L	2.00-3.00PM	3.00PM–4.00PM	4.00-5.00PM								
29 JUNE 2026	MON	L-71 PA (24.3) Carcinomaoftheendometrium	CLINICAL POSTING		67REVISION CLASESS	PPr (18.1)CNS- Schwannoma, Meningioma (Batch A)									
						PH 10.14 Communicate with the patient regarding optimal use of a drug therapy using empathy and professionalism e.g. Oral contraceptives, anti TB drugs etc.									
						MI 6.1 to 6.3 CBL on CNS									
30 JUNE 2026	TUES	L-68REVISION CLASESS	CLINICAL POSTING		SGL 32 FM 2.25 Electrical Injuries	PPr (18.1)CNS- Schwannoma, Meningioma (Batch C)									
						PH 10.14 Communicate with the patient regarding optimal use of a drug therapy using empathy and professionalism e.g. Oral contraceptives, anti TB drugs etc.									
						MI 6.1 to 6.3 CBL on CNS									
01 JULY 2026	WED	L-72 PA (24.4) Ovariantumours	CLINICAL POSTING		MI 8.1, 8.2, 8.3 Syphilis (SGL)	PPr (18.1)CNS- Schwannoma, Meningioma (Batch B)									
						PH 10.14 Communicate with the patient regarding optimal use of a drug therapy using empathy and professionalism e.g. Oral contraceptives, anti TB drugs etc.									
						MI 6.1 to 6.3 CBL on CNS									
02 JULY	THUR	69REVISION CLASESS	CLINICAL		L-73 PA (24.5)	INTEGRATIONREVISION	AETCOM 35 MI-11								

							
2026			POSTING		Trophoblastic diseases: hydatidiform mole, choriocarcinoma.	CLASESS	2.5 Identify, discuss and defend medico-legal, socio-cultural and ethical issues as it pertains to patient autonomy, patient rights and shared responsibility in health care
03 JULY 2026	FRI	L-20 CM8.1E Epidemiological characteristics and control measures including the use of essential laboratory tests at the primary care level for Surface infections AIDS	CLINICAL POSTING		SDL REVISION CLASESS	INTEGRATION MI 8.1, 8.2, 8.3 LGV, granuloma inguinale, soft chancre and genital herpes (SGL)	PANDEMIC-24
							MOD 2.4.5 Describe the role of communities in vaccination programmes.
04 JULY 2026	SAT	MI 8.1, 8.2, 8.3 NGU, Trichomonas vaginalis (L)	SURGERY/ AETCOM		L-21 CM8.1E Epidemiological characteristics and control measures including the use of essential laboratory tests at the primary care level for Surface infections LEPROSY-I	Sports 33	
05 JULY 2026 SUNDAY							
DATE	DAY	9.-10.00AM	10-01PM	L	2.00-3.00PM	3.00PM–4.00PM	4.00-5.00PM
06 JULY 2026	MON	L-74 PA (25.1,25.2) Breast:Non-neoplastic Lesions Enumerate and describe the aetiology, hormonal	CLINICAL POSTING		70 REVISION CLASESS	PPr (28.1) Miscellaneous case discussion (Slide / diagrams) (Batch A)	
						PH 10.16 Demonstrate an understanding of the caution in prescribing drugs likely to produce dependence and recommend the line of management.	
						MI 8.1, 8.4 CBL on urogenital infection	
07 JULY 2026	TUES	L-71 REVISION CLASESS	CLINICAL POSTING		SGL 33 FM 2.25 Electrical Injuries	PPr (28.1) Miscellaneous case discussion (Slide / diagrams) (Batch C)	
						PH 10.16 Demonstrate an understanding of the caution in prescribing drugs likely to produce dependence and recommend the line of management.	
						MI 8.1, 8.4 CBL on urogenital infection	
08 JULY	WED	L-75 PA (25.3)	CLINICAL		MI 8.1, 8.2, 8.3	PPr (28.1) Miscellaneous case discussion (Slide / diagrams) (Batch B)	

2026		Neoplastic lesions of the breast- Classification,	POSTING		Chlamydia trachomatis infections (L)	PH 10.16 Demonstrate an understanding of the caution in prescribing drugs likely to produce dependence and recommend the line of management.	
						MI 8.1, 8.4 CBL on urogenital infection	
09 JULY 2026	THUR	L-72 REVISION CLASSES	CLINICAL POSTING		L-76 PA (26.1,26.2) Thyroid:Differential diagnosis of thyroid nodule. Hyper/Hypothyroidism + Thyroiditis	INTEGRATION MI 1.2, 1.4, 1.5 Ocular and ear infections	AETCOM 36 PH-10 REVISION CLASSES
10 JULY 2026	FRI	L-22 CM 8.1E Epidemiological characteristics and control measures including the use of essential laboratory tests at the primary care level for Surface infections LEPROSY-II	CLINICAL POSTING		INTEGRATION REVISION CLASSES	PA SGD 1.1 – Leishmaniasis, filariasis	PANDEMIC-25 PM 2.1 Standard precaution
11 JULY 2026	SAT	MI 1.2, 1.4, 1.5 Congenital infections (L)	MI EXTRA/ REVISION CLASSES Log book completion, home assignment		L-15 CM 8.1C Epidemiological characteristics and control measures including the use of essential laboratory tests at the primary care level for zoonotic diseases Nipha virus infection, KFD, Chikungunya fever	Sports 34	
12 JULY 2026 SUNDAY							
DATE	DAY	9.-10.00AM	10-01PM	L	2.00-3.00PM	3.00PM–4.00PM	4.00-5.00PM
13 JULY 2026	MON	L-77 PA (26.3) Thyroid tumours	CLINICAL POSTING		73 REVISION CLASSES	PPr (29.1) Instrument Discussion (Batch A) PH 10.17 Demonstrate ability to educate public & patients about various aspects of drug use including drug dependence and OTC drugs. Manual completion and viva	
14 JULY 2026	TUES	L-74 REVISION CLASSES	CLINICAL POSTING		FMT AETCOM FM 4.1 Medical ethics & It's Historical Emergence	PPr (29.1) Instrument Discussion (Batch C) PH 10.17 Demonstrate ability to educate public & patients about various aspects of drug use including drug dependence and OTC drugs. Manual completion and viva	

15 JULY 2026	WED	L-78 PA (26.4) Diabetes Mellitus	CLINICAL POSTING		MI 9.1 Zoonotic infections	PPr (29.1) Instrument Discussion (Batch B)	
						PH 10.17 Demonstrate ability to educate public & patients about various aspects of drug use including drug dependence and OTC drugs.	
						Manual completion and viva	
16 JULY 2026	THUR	75REVISION CLASESS	CLINICAL POSTING		L-79 PA (27.1) OsteomyelitisandMetabolicdiseases	INTEGRATIONREVISION CLASESS	MI 9.4 Onchogenic viruses
17 JULY 2026	FRI	L-23 CM8.1E Epidemiological characteristics and control measures including the use of essential laboratory tests at the primary care level for Surface infections STD	CLINICAL POSTING		SDL MI 9.2, 9.5 Opportunistic, post-transplantation infections, emerging and reemerging infections	PA Tutorial 3.1- Osteomyelitis (Acute/Chronic) / Bone & Soft Tissue Tumor	PANDEMIC-26 GM
18 JULY 2026	SAT	MI 3.10, 3.11, 3.12 Revision class on malaria	PA SDL Case discussion (OSPE)		PANDEMIC-19 CM MOD 2.4.3 Describe the steps to prepare a micro plan for vaccination activity at PHC level.	Sports 35	
19 JULY 2026 SUNDAY							
DATE	DAY	9.-10.00AM	10-01PM	L	2.00-3.00PM	3.00PM–4.00PM	4.00-5.00PM
20 JULY 2026	MON	L-80 PA (27.2), (27.3) Tumors:Primary,osteosarcoma,osteoclastoma, Ewing’ssarcoma,chondrosarcoma,metastatic Soft tissue tumors	CLINICAL POSTING		76REVISION CLASESS	PPr (30.1) Charts Discussion (Batch A)	
						REVISION CLASESS	
						Manual completion and viva	
21JULY 2026	TUES	L-77REVISION CLASESS	CLINICAL POSTING		PA Seminar 11 – Multiple myeloma- BJ Protein / Aplastic anemia / HL	PPr (30.1) Charts Discussion (Batch C)	
						REVISION CLASESS	
						Manual completion and viva	
22 JULY 2026	WED	L-81 PA (29.1, 29.2) CNS Introduction., ClassifyCNStumours- primarygliomaandmeningiomaandmetastatic	CLINICAL POSTING		MI 4.1 Seminar/Tutorial on GI infections	PPr (30.1) Charts Discussion (Batch B)	
						REVISION CLASESS	
						Manual completion and viva	

23 JULY 2026	THUR	78REVISION CLASESS	CLINICAL POSTING		L-82 PA (28.1,28.2, 28.3) Skintumours. Describethetheriskfactorspathogenesis,pathologyandnaturalhistory , Skintumours:pigmented-classificationandmorphological featuresofcommonneviandmalignantmelanoma.	INTEGRATIONREVISION CLASESS	 PANDEMIC-27 2.1 Infection Control: Part II Air borne precautions Contact Precautions (revision)
24 JULY 2026	FRI	L-24 CM8.1E Epidemiological characteristics and control measures including the use of essential laboratory tests at the primary care level for Surface infections Tetanus& Trachoma	CLINICAL POSTING		INTEGRATIONREVISION CLASESS	INTEGRATION MI 1.1, 4.1 Seminar/tutorial on hepatobiliary system	PA SGD – Nephrolithiasis
25 JULY 2026	SAT	MI 7.2, 7.5 Revision class on TB	PH EXTRA/ REVISION CLASESS		PANDEMIC-19 CM MOD 2.4.3 Describe the steps to prepare a micro plan for vaccination activity at PHC level.	Sports 36	
26 JULY 2026 SUNDAY							
DATE	DAY	9.-10.00AM	10-01PM	L	2.00-3.00PM	3.00PM–4.00PM	4.00-5.00PM
27 JULY 2026	MON	L-83 PA (17.1,17.2) Bloodgroupsanditsrelevanceintransfusionmedicineandhematology.Erythroblastosisfetalis.	CLINICAL POSTING		79REVISION CLASESS	PPr (31.1) Gross Specimens Discussion (Batch A)	
						REVISION CLASESS	
						MI 1.1 Revision on Gram/ZN	
28 JULY 2026	TUES	80REVISION CLASESS	CLINICAL POSTING		PA Tutorial 7.2 Metabolic bone disease Rickets/osteomalacia , Paget's disease of bone	PPr (31.1) Gross Specimens Discussion (Batch C)	
						REVISION CLASESS	
						MI 1.1 Revision on Gram/ZN	
29 JULY 2026	WED	L-84 PA (17.3,17.4) BloodComponents&AutologousTransfusion, Bloodtransfusion	CLINICAL POSTING		MI 5.1, 5.2, 5.3 S tissue infections seminar/tutorial on skin and soft	PPr (31.1) Gross Specimens Discussion (Batch B)	
						REVISION CLASESS	
						MI 1.1 Revision on Gram/ZN	
30 JULY	THUR	REVISION CLASESS	CLINICAL		L-85 PA (9.1)	INTEGRATION	AETCOM 37 -PA 11

							
2026			POSTING		Infections andinfestations Typhoidfever.		Aetcom-10 Module 2.6: Bioethics continued: Case studies on autonomy and decision making – Self-directed learning.
31 JULY 2026	FRI	L-25 CM8.1E Epidemiological characteristics and control measures including the use of essential laboratory tests at the primary care level for Emerging and reemerging diseases And Hospital Acquired Infection	CLINICAL POSTING		INTEGRATION MI 6.1 to 6.3 Internal assessment on CNS	INTEGRATIONREVISION CLASESS	PANDEMIC CM 28
							MOD 2.4.6 Describe the cold chain for vaccine storage and delivery.
01 AUG 2026	SAT	MI 6.1, 6.3 Poliomyelitis (revision class)	PA SDL – Library Assignment/ Museum visit		INTEGRATIONREVISION CLASESS	SPORTS 37	
02 AUGUST 2026 SUNDAY							



DEPT. OF PATHOLOGY
HOD SIGN.

DEPT. OF PHARMACOLOGY
HOD SIGN.



DEPT. OF MICROBIOLOGY
HOD SIGN.



DEPT. OF GENERAL MEDICINE
HOD SIGN.

DR. RAMGOPAL SHRITLAHARE
MBBS, MD (Medicine)
Professor and HOD
Dept. of General Medicine
Reg. No. CGMC 463/2005
Shri Balaji Institute of Medical Science
Mowa, Raipur (C.G.)

DEPT. OF GENERAL SURGERY
HOD SIGN.



DEPT. OF ANAESTHESIA & INTENSIVE CARE
HOD SIGN.



DEPT. OF COMMUNITY MED.
HOD SIGN.



DEPT. OF FORENSIC MEDICINE
HOD SIGN.



MEU CO-ORDINATOR



ACADEMIC-DEAN
SBIMS

Dean Academics
Shri Balaji Institute of Medical Science
Mowa, Raipur (C.G.)

DEAN
SBIMS

Dean
Shri Balaji Institute of Medical Science
Mowa, Raipur (C.G.)

CHAIRMAN
SBIMS


Chairman
Shri Balaji Institute of Medical Science
Mowa, Raipur (C.G.)

SHRI BALAJI INSTITUTE OF MEDICAL SCIENCE RAIPUR (C.G.)

ACADEMIC TIME TABLE –MBBS BATCH 2024 PHASE II TEACHING SESSION - 08 OCT 2025 - SEPTEMBER 2026

PRE- UNIVERSITY EXAMINATION				
Date	Day	Subject	Time	
03/08/2026	Monday	Pathology-I	10:00 am -01 pm	
04/08/2026	Tuesday	Pathology-II		
06/08/2026	Thursday	Pharmacology- I		
07/08/2026	Friday	Pharmacology- II		
10/08/2026	Monday	Microbiology - I		
11/08/2026	Tuesday	Microbiology - II		
PRACTICAL EXAMINATION				
Date	Days	Pathology	Pharmacology	Microbiology
12/08/2026	Wednesday	(Batch -A) -1-50	(Batch -B) -51-100	(Batch -C) 101-150
13/08/2026	Thursday	(Batch -C) 101-150	(Batch -A) -1-50	(Batch -B) -51-100
14/08/2026	Friday	(Batch -B) -51-100	(Batch -C) - 101-150	(Batch -A) -1-50


DEPT. OF PATHOLOGY
HOD SIGN

DEPT. OF PHARMACOLOGY
HOD SIGN




DEPT. OF MICROBIOLOGY
HOD SIGN




MEU CO-ORDINATOR




ACADEMIC – DEAN
SBIMS
Dean Academics
Shri Balaji Institute of Medical Science
Mowa, Raipur (C.G.)



DEAN
SBIMS
Dean
Shri Balaji Institute of Medical Science
Mowa, Raipur (C.G.)



CHAIRMAN
SBIMS
Chairman
Shri Balaji Institute of Medical Science
Mowa, Raipur (C.G.)



SHRI BALAJI INSTITUTE OF MEDICAL SCIENCE RAIPUR (C.G.)

ACADEMIC TIME TABLE –MBBS BATCH 2024 PHASE II TEACHING SESSION - 08 OCT 2025 - SEPTEMBER 2026



पंडित दीनदयाल उपाध्याय स्मृति स्वास्थ्य विज्ञान एवं
आयुष विश्वविद्यालय छत्तीसगढ़

उपरवारा सेक्टर -40, नवा-रायपुर अटल नगर (छ0ग0)-493661
(छ0ग0 अधिनियम क्र0 21/2008 द्वारा स्थापित)

www.ddumhsauctg.ac.in

No./ F- E- 1(1)/ NS - 17 /DUHS/EXAM/2025/ 9156 -

Raipur, Dated 10/05/2025 2025

// अधिसूचना //

पंडित दीनदयाल उपाध्याय स्मृति स्वास्थ्य विज्ञान एवं आयुष विश्वविद्यालय, छत्तीसगढ़ नवा-रायपुर, अटल नगर द्वारा आयोजित की जाने वाली एम.बी.बी.एस. द्वितीय वर्ष की मुख्य परीक्षा सितम्बर-2026 हेतु परीक्षा आवेदन जमा करने महत्वपूर्ण तिथियाँ, परीक्षा शुल्क एवं समय-सारिणी निम्नानुसार अधिसूचित की जाती है-

1. परीक्षा आवेदन जमा करने हेतु महत्वपूर्ण तिथियाँ:-

क्र.	छात्र/छात्राओं द्वारा ऑनलाईन परीक्षा आवेदन जमा करने की प्रारंभ तिथि	छात्र/छात्राओं द्वारा ऑनलाईन परीक्षा आवेदन जमा करने की अंतिम तिथि	विलम्ब शुल्क (परीक्षा शुल्क में 10 प्रतिशत विलम्ब शुल्क देय होगा।) के साथ ऑनलाईन परीक्षा आवेदन जमा करने की अंतिम तिथि	महाविद्यालय द्वारा विश्वविद्यालय को ऑनलाईन परीक्षा आवेदन अग्रेषित करने हेतु अंतिम तिथि
1.	17.08.2026	24.08.2026	25.08.2026	27.08.2026

❖ नोट:- 1. समस्त छात्र/छात्राओं के परीक्षा आवेदन परीक्षा आवेदन वि0वि0 के वेबसाइट पर उपलब्ध TCSion Student login के माध्यम से स्वीकार किये जावेंगे।

2. परीक्षा आवेदन शुल्क :-

परीक्षा का नाम	मुख्य / नियमित	परीक्षा शुल्क (रुपए में)			
		एक विषय	दो विषय	दो से अधिक विषय	अंकसूची शुल्क
M.B.B.S.	4500.00	3000.00	3500.00	4500.00	100.00

3. समय-सारिणी :-

M.B.B.S. EXAMINATION

(Time - 11:00 AM to 02:00 PM)

S. No.	Date of Examination	M.B.B.S. Second Year
1	05.09.2026	Pathology - I
2	07.09.2026	Pathology - II
3	09.09.2026	Pharmacology - I
4	11.09.2026	Pharmacology - II
5	15.09.2026	Microbiology - I
6	17.09.2026	Microbiology - II

Note:- Practical to be held before date :- 30-09-2026

// क्रमशः 2 //

4. महाविद्यालयवार परीक्षा केन्द्रों की सूची पृथक से शीघ्र ही जारी कर दी जावेगी।

✍